CN109010254A - 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 - Google Patents
适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 Download PDFInfo
- Publication number
- CN109010254A CN109010254A CN201810378167.XA CN201810378167A CN109010254A CN 109010254 A CN109010254 A CN 109010254A CN 201810378167 A CN201810378167 A CN 201810378167A CN 109010254 A CN109010254 A CN 109010254A
- Authority
- CN
- China
- Prior art keywords
- linaclotide
- months
- desiccant
- sealing container
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract description 37
- 229920001184 polypeptide Polymers 0.000 title abstract description 12
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract description 12
- 239000007787 solid Substances 0.000 title abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 4
- 102100034605 Atrial natriuretic peptide receptor 3 Human genes 0.000 title description 5
- 101000924488 Homo sapiens Atrial natriuretic peptide receptor 3 Proteins 0.000 title description 5
- 239000000018 receptor agonist Substances 0.000 title description 4
- 229940044601 receptor agonist Drugs 0.000 title description 4
- 108010024409 linaclotide Proteins 0.000 claims abstract description 247
- 229960000812 linaclotide Drugs 0.000 claims abstract description 247
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 claims abstract description 243
- 238000003860 storage Methods 0.000 claims abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 claims description 62
- 238000007789 sealing Methods 0.000 claims description 54
- 239000002274 desiccant Substances 0.000 claims description 52
- 239000002552 dosage form Substances 0.000 claims description 43
- 230000002829 reductive effect Effects 0.000 claims description 26
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000004587 chromatography analysis Methods 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 abstract description 68
- 238000000034 method Methods 0.000 abstract description 40
- 150000001413 amino acids Chemical group 0.000 abstract description 24
- 150000003839 salts Chemical class 0.000 abstract description 18
- 239000003814 drug Substances 0.000 abstract description 17
- 238000004519 manufacturing process Methods 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 9
- ISWAQPWFWKGCAL-ACZMJKKPSA-N Cys-Cys-Glu Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(O)=O ISWAQPWFWKGCAL-ACZMJKKPSA-N 0.000 abstract description 4
- CGDZGRLRXPNCOC-SRVKXCTJSA-N Tyr-Cys-Cys Chemical compound SC[C@@H](C(O)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 CGDZGRLRXPNCOC-SRVKXCTJSA-N 0.000 abstract description 4
- 108010069495 cysteinyltyrosine Proteins 0.000 abstract description 4
- PLTGTJAZQRGMPP-FXQIFTODSA-N Asn-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(N)=O PLTGTJAZQRGMPP-FXQIFTODSA-N 0.000 abstract description 2
- ALNKNYKSZPSLBD-ZDLURKLDSA-N Cys-Thr-Gly Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O ALNKNYKSZPSLBD-ZDLURKLDSA-N 0.000 abstract description 2
- 108010010430 asparagine-proline-alanine Proteins 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 92
- 239000000203 mixture Substances 0.000 description 85
- 239000011248 coating agent Substances 0.000 description 51
- -1 formaldehyde imines Chemical class 0.000 description 51
- 238000000576 coating method Methods 0.000 description 49
- 239000000047 product Substances 0.000 description 48
- 239000002775 capsule Substances 0.000 description 44
- 239000000945 filler Substances 0.000 description 37
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Natural products O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 34
- 150000003141 primary amines Chemical class 0.000 description 34
- 239000011324 bead Substances 0.000 description 31
- 150000001768 cations Chemical class 0.000 description 29
- 239000000654 additive Substances 0.000 description 28
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 27
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 27
- 235000005772 leucine Nutrition 0.000 description 27
- 229960003136 leucine Drugs 0.000 description 27
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 21
- 235000001014 amino acid Nutrition 0.000 description 21
- 239000000853 adhesive Substances 0.000 description 20
- 230000001070 adhesive effect Effects 0.000 description 20
- 206010010774 Constipation Diseases 0.000 description 19
- 230000003647 oxidation Effects 0.000 description 19
- 238000007254 oxidation reaction Methods 0.000 description 19
- 235000002639 sodium chloride Nutrition 0.000 description 19
- 230000000996 additive effect Effects 0.000 description 18
- 239000008107 starch Substances 0.000 description 17
- 229920002472 Starch Polymers 0.000 description 16
- 229920000159 gelatin Polymers 0.000 description 16
- 235000019322 gelatine Nutrition 0.000 description 16
- 239000002245 particle Substances 0.000 description 16
- 235000019698 starch Nutrition 0.000 description 16
- 239000001828 Gelatine Substances 0.000 description 14
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000000314 lubricant Substances 0.000 description 14
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 14
- 239000008108 microcrystalline cellulose Substances 0.000 description 14
- 229940016286 microcrystalline cellulose Drugs 0.000 description 14
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 12
- 239000001110 calcium chloride Substances 0.000 description 12
- 229910001628 calcium chloride Inorganic materials 0.000 description 12
- 125000001072 heteroaryl group Chemical group 0.000 description 12
- 239000000413 hydrolysate Substances 0.000 description 12
- 208000002551 irritable bowel syndrome Diseases 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 11
- 230000001133 acceleration Effects 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 description 10
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- 125000003118 aryl group Chemical group 0.000 description 8
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 8
- 201000006549 dyspepsia Diseases 0.000 description 8
- 235000006109 methionine Nutrition 0.000 description 8
- 229930182817 methionine Natural products 0.000 description 8
- 229960004452 methionine Drugs 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- 239000001506 calcium phosphate Substances 0.000 description 7
- 150000001721 carbon Chemical group 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- SERLAGPUMNYUCK-YJOKQAJESA-N 6-O-alpha-D-glucopyranosyl-D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-YJOKQAJESA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 6
- 229960002713 calcium chloride Drugs 0.000 description 6
- 235000011148 calcium chloride Nutrition 0.000 description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 6
- 239000001913 cellulose Substances 0.000 description 6
- 230000013872 defecation Effects 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- 229910001629 magnesium chloride Inorganic materials 0.000 description 6
- 229960002337 magnesium chloride Drugs 0.000 description 6
- 235000011147 magnesium chloride Nutrition 0.000 description 6
- 125000004430 oxygen atom Chemical group O* 0.000 description 6
- 238000001694 spray drying Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000004246 zinc acetate Substances 0.000 description 6
- 235000013904 zinc acetate Nutrition 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 239000005864 Sulphur Substances 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 229960003767 alanine Drugs 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 235000014705 isoleucine Nutrition 0.000 description 5
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 5
- 229960000310 isoleucine Drugs 0.000 description 5
- 239000000905 isomalt Substances 0.000 description 5
- 235000010439 isomalt Nutrition 0.000 description 5
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 5
- 229920000609 methyl cellulose Polymers 0.000 description 5
- 235000010981 methylcellulose Nutrition 0.000 description 5
- 239000001923 methylcellulose Substances 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 4
- 229910000389 calcium phosphate Inorganic materials 0.000 description 4
- 235000011010 calcium phosphates Nutrition 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000005243 fluidization Methods 0.000 description 4
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 238000003259 recombinant expression Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000002269 spontaneous effect Effects 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000013112 stability test Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 3
- 229920003119 EUDRAGIT E PO Polymers 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000004372 Polyvinyl alcohol Substances 0.000 description 3
- 235000021355 Stearic acid Nutrition 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 206010000059 abdominal discomfort Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 229960005261 aspartic acid Drugs 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 125000002619 bicyclic group Chemical group 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 3
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical group COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 3
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229960005069 calcium Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 3
- 235000011092 calcium acetate Nutrition 0.000 description 3
- 239000001639 calcium acetate Substances 0.000 description 3
- 229960005147 calcium acetate Drugs 0.000 description 3
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 3
- 235000013539 calcium stearate Nutrition 0.000 description 3
- 229940095672 calcium sulfate Drugs 0.000 description 3
- 235000011132 calcium sulphate Nutrition 0.000 description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 3
- 125000002091 cationic group Chemical group 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 229960002743 glutamine Drugs 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 229960002885 histidine Drugs 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 150000002466 imines Chemical class 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000011654 magnesium acetate Substances 0.000 description 3
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 3
- 235000011285 magnesium acetate Nutrition 0.000 description 3
- 229940069446 magnesium acetate Drugs 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 235000008729 phenylalanine Nutrition 0.000 description 3
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 239000001103 potassium chloride Substances 0.000 description 3
- 235000011164 potassium chloride Nutrition 0.000 description 3
- 229960002816 potassium chloride Drugs 0.000 description 3
- 235000019814 powdered cellulose Nutrition 0.000 description 3
- 229920003124 powdered cellulose Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 235000013580 sausages Nutrition 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 235000008521 threonine Nutrition 0.000 description 3
- 229960002898 threonine Drugs 0.000 description 3
- 229960004799 tryptophan Drugs 0.000 description 3
- 239000004474 valine Substances 0.000 description 3
- 229960004295 valine Drugs 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- DWPCPZJAHOETAG-IMJSIDKUSA-N L-lanthionine Chemical compound OC(=O)[C@@H](N)CSC[C@H](N)C(O)=O DWPCPZJAHOETAG-IMJSIDKUSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 208000007542 Paresis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 206010068620 Post procedural constipation Diseases 0.000 description 2
- 229920003110 Primojel Polymers 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- WYKJENSCCRJLRC-ZDLURKLDSA-N Thr-Gly-Cys Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CS)C(=O)O)N)O WYKJENSCCRJLRC-ZDLURKLDSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 238000005054 agglomeration Methods 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 2
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000014797 chronic intestinal pseudoobstruction Diseases 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 229940096516 dextrates Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229960002442 glucosamine Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 229960002989 glutamic acid Drugs 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 208000024798 heartburn Diseases 0.000 description 2
- CPSYWNLKRDURMG-UHFFFAOYSA-L hydron;manganese(2+);phosphate Chemical compound [Mn+2].OP([O-])([O-])=O CPSYWNLKRDURMG-UHFFFAOYSA-L 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229960000367 inositol Drugs 0.000 description 2
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000832 lactitol Substances 0.000 description 2
- 235000010448 lactitol Nutrition 0.000 description 2
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 2
- 229960003451 lactitol Drugs 0.000 description 2
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 2
- 238000005461 lubrication Methods 0.000 description 2
- 239000000391 magnesium silicate Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 229960003390 magnesium sulfate Drugs 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 229940071125 manganese acetate Drugs 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- 235000002867 manganese chloride Nutrition 0.000 description 2
- 229940099607 manganese chloride Drugs 0.000 description 2
- 229940077478 manganese phosphate Drugs 0.000 description 2
- 229940099596 manganese sulfate Drugs 0.000 description 2
- 239000011702 manganese sulphate Substances 0.000 description 2
- 235000007079 manganese sulphate Nutrition 0.000 description 2
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 description 2
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 2
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 2
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 239000011574 phosphorus Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 235000014786 phosphorus Nutrition 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 235000011056 potassium acetate Nutrition 0.000 description 2
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 2
- 229910052939 potassium sulfate Inorganic materials 0.000 description 2
- 235000011151 potassium sulphates Nutrition 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 2
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 235000002374 tyrosine Nutrition 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 2
- 229910000165 zinc phosphate Inorganic materials 0.000 description 2
- 229940077935 zinc phosphate Drugs 0.000 description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 2
- 229960001763 zinc sulfate Drugs 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- LCTORNIWLGOBPB-GASJEMHNSA-N (3r,4s,5s,6r)-2-amino-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound NC1(O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O LCTORNIWLGOBPB-GASJEMHNSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N 1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid Chemical compound C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- VJROPLWGFCORRM-UHFFFAOYSA-N 2-methylbutan-1-amine Chemical compound CCC(C)CN VJROPLWGFCORRM-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- KDDQRKBRJSGMQE-UHFFFAOYSA-N 4-thiazolyl Chemical group [C]1=CSC=N1 KDDQRKBRJSGMQE-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 201000005078 Colonic Pseudo-Obstruction Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000000820 Enterotoxin Receptors Human genes 0.000 description 1
- 108010001687 Enterotoxin Receptors Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- YKFRUJSEPGHZFJ-UHFFFAOYSA-N N-trimethylsilylimidazole Chemical compound C[Si](C)(C)N1C=CN=C1 YKFRUJSEPGHZFJ-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010054048 Postoperative ileus Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- ALJGSKMBIUEJOB-FXQIFTODSA-N Pro-Ala-Cys Chemical compound C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@@H]1CCCN1 ALJGSKMBIUEJOB-FXQIFTODSA-N 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- NGRKPYGAOGPOEJ-UHFFFAOYSA-N [Hg].C1=CC=CC=C1.[N+](=O)(O)[O-] Chemical compound [Hg].C1=CC=CC=C1.[N+](=O)(O)[O-] NGRKPYGAOGPOEJ-UHFFFAOYSA-N 0.000 description 1
- MSKSOBAQMWJYTJ-UHFFFAOYSA-N [Mg].OP(O)(O)=O Chemical compound [Mg].OP(O)(O)=O MSKSOBAQMWJYTJ-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- HDYRYUINDGQKMC-UHFFFAOYSA-M acetyloxyaluminum;dihydrate Chemical compound O.O.CC(=O)O[Al] HDYRYUINDGQKMC-UHFFFAOYSA-M 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000004705 aldimines Chemical class 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229940009827 aluminum acetate Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- FYHXNYLLNIKZMR-UHFFFAOYSA-N calcium;carbonic acid Chemical compound [Ca].OC(O)=O FYHXNYLLNIKZMR-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- NNBZCPXTIHJBJL-UHFFFAOYSA-N decalin Chemical compound C1CCCC2CCCCC21 NNBZCPXTIHJBJL-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000006356 dehydrogenation reaction Methods 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 206010060865 duodenogastric reflux Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000005454 flavour additive Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005114 heteroarylalkoxy group Chemical group 0.000 description 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 238000007373 indentation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000003641 microbiacidal effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-N o-dicarboxybenzene Natural products OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229960000540 polacrilin potassium Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 229960004109 potassium acetate Drugs 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000011253 protective coating Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 125000004308 pyranonyl group Chemical group O1C(C(=CC=C1)*)=O 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002206 pyridazin-3-yl group Chemical group [H]C1=C([H])C([H])=C(*)N=N1 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical class N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- JXKPEJDQGNYQSM-UHFFFAOYSA-M sodium propionate Chemical compound [Na+].CCC([O-])=O JXKPEJDQGNYQSM-UHFFFAOYSA-M 0.000 description 1
- 235000010334 sodium propionate Nutrition 0.000 description 1
- 239000004324 sodium propionate Substances 0.000 description 1
- 229960003212 sodium propionate Drugs 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 229960000314 zinc acetate Drugs 0.000 description 1
- 229960001939 zinc chloride Drugs 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D81/00—Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents
- B65D81/24—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants
- B65D81/26—Adaptations for preventing deterioration or decay of contents; Applications to the container or packaging material of food preservatives, fungicides, pesticides or animal repellants with provision for draining away, or absorbing, or removing by ventilation, fluids, e.g. exuded by contents; Applications of corrosion inhibitors or desiccators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
- G01N30/02—Column chromatography
- G01N2030/022—Column chromatography characterised by the kind of separation mechanism
- G01N2030/027—Liquid chromatography
Abstract
本文描述了适合口服给药的稳定的利那洛肽固体制剂,也描述了制备这样的制剂的方法。本文所述的制剂包含由氨基酸序列Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr组成的多肽(“利那洛肽”)或其药学上可接受的盐。本文所述的利那洛肽制剂是稳定的,且具有对于生产、储存和分配该药物而言足够的贮存期限。
Description
本申请是以下申请的分案申请:申请日:2009年8月14日;申请号:201510363805.7;发明名称:同上。
技术领域
本公开内容涉及适合口服给药的鸟苷酸环化酶-C受体激动剂多肽的固体制剂和制备这样的制剂的方法。
优先权声明
本申请要求2008年8月15日提交的美国申请系列号61/089,422和2009年8月3日提交的标题为“Stable Solid Formulation of a GC-C Receptor Agonist PolypeptideSuitable for Oral Administration”的美国临时申请的优先权。前述申请的所有内容通过引用并入本文。
背景技术
许多治疗多肽在水性溶液中配制,因为它们在该形式是最高活性的。但是,大多数多肽在水性溶液中不是特别稳定,所以制剂经常具有短的半衰期,且需要冷冻。尽管可以通过冷冻-干燥、喷雾干燥或其它方法来干燥多肽的水性溶液,这样干燥的制剂也可能是不稳定的,且具有与多肽的水性溶液相比降低的活性。在水性溶液中和在干燥的制剂中发生的典型分解机理包括聚集和氧化性或水解性降解。因而,由于它们的有限的稳定性,大多数治疗多肽(无论在水性溶液中还是干燥的)都储存在冷冻条件下。
利那洛肽(Linaclotide)是一种具有氨基酸序列Cys Cys Glu Tyr Cys Cys AsnPro Ala Cys Thr Gly Cys Tyr的肽,其活化鸟苷酸环化酶-C(GC-C)受体。利那洛肽(其可以口服给药)可用于治疗胃肠道障碍和病症,包括肠易激综合征(IBS)和慢性便秘(CC)。为了避免随时间降解,必须冷冻包含利那洛肽的制剂。但是,对于药物的商业分配和患者的储存而言,冷冻是不方便的。因而,需要具有在室温稳定至少12个月的固体利那洛肽制剂。
发明内容
本文描述了适合口服给药的稳定的利那洛肽固体制剂,也描述了制备这样的制剂的方法。本文所述的制剂包含由氨基酸序列Cys Cys Glu Tyr Cys Cys Asn Pro Ala CysThr Gly Cys Tyr组成的多肽(“利那洛肽”)或其药学上可接受的盐。
本文所述的利那洛肽制剂是稳定的,且具有对于生产、储存和分配药物而言足够的贮存期限。例如,预期本文所述的制剂具有在室温贮存条件(例如,25℃/60%相对湿度(RH))下至少12个月的贮存期限。在其它实施方案中,预期本文所述的制剂具有在室温贮存条件(例如,25℃/60%RH)下至少18个月或至少24个月的贮存期限。
在有些实施方案中,描述了这样的制剂,其中当在加速条件(40℃/75%RH)下储存包装的样品时,相对于利那洛肽参比标准通过高压液相色谱法(HPLC)测得,当在基于重量/重量的测定中评估时,3个月后在组合物中有≥95%起始量的利那洛肽保留不变。在其它实施方案中,当在加速条件(40℃/75%RH)下储存包装的样品时,至少6个月后在组合物中有≥90%起始量的利那洛肽保留不变。在其它实施方案中,描述了这样的制剂,其中当在加速条件(40℃/75%RH)下储存包装的样品时,通过HPLC以面积百分比测定的利那洛肽的色谱纯度在至少3个月的过程中保留≥95%。在其它实施方案中,当在加速条件(40℃/75%RH)下储存包装的样品时,通过HPLC以面积百分比测定的利那洛肽的色谱纯度在至少6个月的过程中保留≥90%。因而,例如,不超过约10%的利那洛肽被降解为其它产物,诸如利那洛肽的氧化产物、利那洛肽的水解产物或利那洛肽的甲醛-介导的亚胺产物(“甲醛亚胺产物”)。
在一个实施方案中,本发明包括包含利那洛肽的药物组合物,其中在装有干燥剂的密封容器中在25℃在60%相对湿度储存药物组合物18个月或24个月后,利那洛肽的色谱纯度降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在25℃在60%相对湿度储存药物组合物18个月或24个月后,利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%、4%或2%。在另一个实施方案中,本发明包括包含利那洛肽的药物组合物,其中在装有干燥剂的密封容器中在40℃在75%相对湿度储存药物组合物3个月或6个月后,利那洛肽的色谱纯度降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在40℃在75%相对湿度储存药物组合物3个月或6个月后,利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%、4%或2%。
在一个实施方案中,本发明包括包含利那洛肽的药物组合物的单位剂型,其中在装有干燥剂的密封容器中在25℃在60%相对湿度储存单位剂型18个月或24个月后,利那洛肽的色谱纯度降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在25℃在60%相对湿度储存单位剂型18个月或24个月后,利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%、4%或2%。在另一个实施方案中,本发明包括包含利那洛肽的药物组合物的单位剂型,其中在装有干燥剂的密封容器中在40℃在75%相对湿度储存单位剂型3个月或6个月后,利那洛肽的色谱纯度降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在40℃在75%相对湿度储存单位剂型3个月或6个月后,利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%、4%或2%。
在一个实施方案中,本发明包括密封容器,其装有包含利那洛肽的药物组合物的多个单位剂型,其中装有干燥剂的密封容器在25℃在60%相对湿度储存18个月或24个月后,利那洛肽的色谱纯度降低了小于10%。在另一个实施方案中,装有干燥剂的密封容器在25℃在60%相对湿度储存18个月或24个月后,利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%、4%或2%。在另一个实施方案中,本发明包括密封容器,其含有包含利那洛肽的药物组合物的多个单位剂型,其中装有干燥剂的密封容器在40℃在75%相对湿度储存3个月或6个月后,利那洛肽的色谱纯度降低了小于10%。在另一个实施方案中,装有干燥剂的密封容器在40℃在75%相对湿度储存3个月或6个月后,利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%、4%或2%。
在一个实施方案中,本发明包括包含利那洛肽的药物组合物,其中在装有干燥剂的密封容器中在25℃在60%相对湿度储存药物组合物18个月或24个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在25℃在60%相对湿度储存药物组合物18个月或24个月后,基于重量/重量测得的利那洛肽的测定值降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。在另一个实施方案中,本发明包括包含利那洛肽的药物组合物,其中在装有干燥剂的密封容器中在40℃在75%相对湿度储存药物组合物3个月或6个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在40℃在75%相对湿度储存药物组合物3个月或6个月后,利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。
在一个实施方案中,本发明包括包含利那洛肽的药物组合物的单位剂型,其中在装有干燥剂的密封容器中在25℃在60%相对湿度储存单位剂型18个月或24个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在25℃在60%相对湿度储存单位剂型18个月或24个月后,基于重量/重量测得的利那洛肽的测定值降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。在另一个实施方案中,本发明包括包含利那洛肽的药物组合物的单位剂型,其中在装有干燥剂的密封容器中在40℃在75%相对湿度储存单位剂型3个月或6个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。在另一个实施方案中,在装有干燥剂的密封容器中在40℃在75%相对湿度储存单位剂型3个月或6个月后,基于重量/重量测得的利那洛肽的测定值降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。
在一个实施方案中,本发明包括密封容器,其装有包含利那洛肽的药物组合物的多个单位剂型,其中在装有干燥剂的密封容器中在25℃在60%相对湿度储存密封容器18个月或24个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。在另一个实施方案中,装有干燥剂的密封容器在25℃在60%相对湿度储存18个月或24个月后,基于重量/重量测得的利那洛肽的测定值降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。在另一个实施方案中,本发明包括密封容器,其装有包含利那洛肽的药物组合物的多个单位剂型,其中装有干燥剂的密封容器在40℃在75%相对湿度储存3个月或6个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。在另一个实施方案中,装有干燥剂的密封容器在40℃在75%相对湿度储存3个月或6个月后,基于重量/重量测得的利那洛肽的测定值降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。
在有些实施方案中,提供了包含利那洛肽和水解产物的药物组合物,所述水解产物包含:
在有些实施方案中,所述水解产物占组合物的小于约15%(按重量计算)、组合物的小于约10%(按重量计算)、组合物的小于约7%(按重量计算)或组合物的小于约5%(按重量计算)。在其它实施方案中,所述水解产物占组合物的约0.01%至约15%(按重量计算)、组合物的约0.05%至约10%(按重量计算)、组合物的约0.05%至约7%(按重量计算)或组合物的约0.05%至约5%(按重量计算)。在其它实施方案中,提供了治疗有此需要的患者的胃肠道障碍的方法,所述方法包括,施用包含利那洛肽和水解产物的药物组合物。
在有些实施方案中,提供了包含利那洛肽和甲醛亚胺产物的药物组合物,所述甲醛亚胺产物包含:
在有些实施方案中,所述甲醛亚胺产物占组合物的小于约15%(按重量计算)、组合物的小于约10%(按重量计算)、组合物的小于约7%(按重量计算)或组合物的小于约5%(按重量计算)。在其它示例性的实施方案中,所述甲醛亚胺产物占组合物的约0.01%至约15%(按重量计算)、组合物的约0.05%至约10%(按重量计算)、组合物的约0.05%至约7%(按重量计算)或组合物的约0.05%至约5%(按重量计算)。在其它实施方案中,提供了治疗有此需要的患者的胃肠道障碍的方法,所述方法包括,施用包含利那洛肽和甲醛亚胺产物的药物组合物。
在有些实施方案中,提供了包含利那洛肽和利那洛肽氧化产物的药物组合物。在一个实施方案中,所述利那洛肽氧化产物具有1542.8的分子量,其最可能随着单个氧原子添加到利那洛肽的6个半胱氨酰硫之一上面而形成。下面描述了所述产物的一种可能的结构,尽管本领域技术人员会认识到,氧原子可以连接到其它5个硫中的任一个上:
在另一个实施方案中,可能向利那洛肽添加超过一个氧原子,每个添加的氧原子会使它的分子量增加16AU。
在有些实施方案中,所述利那洛肽氧化产物占组合物的小于约15%(按重量计算)、组合物的小于约10%(按重量计算)、组合物的小于约7%(按重量计算)或组合物的小于约5%(按重量计算)。在其它示例性的实施方案中,所述利那洛肽氧化产物占组合物的约0.01%至约15%(按重量计算)、组合物的约0.05%至约10%(按重量计算)、组合物的约0.05%至约7%(按重量计算)或组合物的约0.05%至约5%(按重量计算)。在其它实施方案中,提供了治疗有此需要的患者的胃肠道障碍的方法,所述方法包括,施用包含利那洛肽和利那洛肽氧化产物的药物组合物。
通过对比(例如通过HPLC)样品中利那洛肽的量和利那洛肽参比标准,可以测得基于重量/重量的测定值(“重量/重量测定”)。如本文使用的,将在室温或在加速条件下储存后在指定的时间点处(例如,在加速条件[40℃/75%RH]下储存3或6个月,或在室温条件[25℃/60%RH]下储存12、18或24个月)组合物中利那洛肽的重量,与在起始时间(例如,当将药物组合物释放用于临床或患者使用时的时间(“释放日”))处组合物中利那洛肽的重量相对比,以提供重量/重量测定值。例如,在加速条件(40℃/75%RH)下储存指定的时间后,测量组合物中利那洛肽的重量,并与在释放日存在于样品中的利那洛肽的重量相对比。在另一个实施例中,在室温条件(25℃/60%RH)下储存指定的时间后,测量组合物中利那洛肽的重量,并与在释放日存在于样品中的利那洛肽的重量相对比。因而,短语“当在加速条件(40℃/75%RH)下储存包装的样品时,在组合物中的≥90%起始量的利那洛肽在至少6个月后保留不变”是指,在加速条件下储存至少6个月后在基于重量/重量的测定中通过HPLC测定而测得的组合物中的利那洛肽的重量是在起始时间(例如,所述利那洛肽组合物的释放日)在组合物中存在的利那洛肽的量的≥90%。
通过在本文所述条件下进行HPLC,可以评估利那洛肽的色谱纯度。测量利那洛肽峰下面积,并与排除溶剂峰和任意非多肽相关峰(即,在安慰剂中可以观察到的与赋形剂有关的峰)的所有峰下总面积相对比。如本文使用的,将在室温或加速条件下储存后在指定的时间点处(例如,在加速条件[40℃/75%RH]下储存3或6个月,或在室温条件[25℃/60%RH]下储存12、18或24个月)组合物中利那洛肽的色谱纯度,与在起始时间(例如,当将药物组合物释放用于临床或患者使用时的时间(“释放日”))处组合物中利那洛肽的色谱纯度相对比,以提供色谱纯度值。例如,在加速条件(40℃/75%RH)下储存指定的时间后,测量组合物中利那洛肽的色谱纯度,并与在释放日处组合物中的利那洛肽的色谱纯度相对比。在另一个实施例中,在室温条件(25℃/60%RH)下储存指定的时间后,测量组合物中利那洛肽的色谱纯度,并与在释放日处组合物中的利那洛肽的色谱纯度相对比。
本公开内容表征了制备包含利那洛肽或其药学上可接受的盐的药物组合物的方法,所述方法包括:(a)提供溶液,例如,水性溶液(“包衣溶液”),其包含:(i)利那洛肽或其药学上可接受的盐;(ii)选自Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+的阳离子和/或空间阻碍的伯胺(例如,亮氨酸)和,任选地,(iii)药学上可接受的粘合剂;和(b)将包衣溶液应用于药学上可接受的填充剂,以产生多肽-包被的填充剂(例如,通过用包衣溶液喷雾、混合或包被药学上可接受的填充剂)。所述方法可以任选地包括下述一项或多项:(i)混合该多肽-包被的填充剂和药学上可接受的助流剂、药学上可接受的润滑剂或作为助流剂和润滑剂二者的药学上可接受的添加剂;(ii)混合该多肽-包被的填充剂和非多肽-包被的填充剂,(iii)混合该多肽-包被的填充剂和其它添加剂;(iii)将药学上可接受的包衣添加剂应用于多肽-包被的填充剂。最终的药物组合物可以放入胶囊(例如,明胶胶囊)中,或用于形成片剂。
已经发现,选自Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+的阳离子可用于抑制在储存期间利那洛肽的氧化产物的形成。还已经发现,空间阻碍的伯胺(例如,亮氨酸)可用于抑制在储存期间利那洛肽的甲醛亚胺加合物(“甲醛亚胺产物”)的形成。因而,包含选自Mg2+、Ca2+、Zn2 +、Mn2+、K+、Na+或Al3+的阳离子(例如,选自Zn2+、Mg2+或Ca2+的二价阳离子)和/或空间阻碍的伯胺(诸如氨基酸)的利那洛肽制剂,具有对于生产、储存和分配药物而言足够的贮存期限(通过色谱纯度和/或通过重量/重量测定测得)。此外,尽管单独的空间阻碍的胺的存在可以增加在储存期间利那洛肽的水解产物的形成,空间阻碍的伯胺和阳离子的组合,例如,亮氨酸和Ca2+的组合,会抑制在储存期间利那洛肽的水解产物以及利那洛肽的氧化产物的形成,导致甚至更大的总稳定性,正如通过重量/重量分析和/或通过色谱纯度测得的。
在有些实施方案中,提供了药物组合物,其包含药学上可接受的载体、利那洛肽和一种或多种选自下述的试剂:Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+和空间阻碍的伯胺,其中与不含所述试剂的药物组合物相比,所述试剂会改善组合物的至少一种性质。在其它实施方案中,所述试剂是Mg2+、Ca2+或Zn2+。在另一个实施方案中,所述试剂是Ca2+。在有些实施方案中,所述阳离子以(但不限于)醋酸镁、氯化镁、磷酸镁、硫酸镁、醋酸钙、氯化钙、磷酸钙、硫酸钙、乙酸锌、氯化锌、磷酸锌、硫酸锌、醋酸锰、氯化锰、磷酸锰、硫酸锰、乙酸钾、氯化钾、磷酸钾、硫酸钾、乙酸钠、氯化钠、磷酸钠、硫酸钠、醋酸铝、氯化铝、磷酸铝或硫酸铝提供。在其它实施方案中,所述阳离子以氯化镁、氯化钙、磷酸钙、硫酸钙、乙酸锌、氯化锰、氯化钾、氯化钠或氯化铝提供。在其它实施方案中,所述阳离子以氯化钙、氯化镁或乙酸锌提供。
在另一个实施方案中,所述试剂是空间阻碍的伯胺。在进一步实施方案中,所述空间阻碍的伯胺是氨基酸。在还进一步实施方案中,所述氨基酸是天然存在的氨基酸。在还又进一步实施方案中,所述天然存在的氨基酸选自下面一组:组氨酸、苯丙氨酸、丙氨酸、谷氨酸、天冬氨酸、谷氨酰胺、亮氨酸、蛋氨酸、天冬酰胺、酪氨酸、苏氨酸、异亮氨酸、色氨酸、蛋氨酸和缬氨酸;更进一步,所述天然存在的氨基酸是亮氨酸、异亮氨酸、丙氨酸或蛋氨酸;在另一个实施方案中,所述天然存在的氨基酸是亮氨酸或蛋氨酸;更进一步,所述天然存在的氨基酸是亮氨酸。在另一个实施方案中,所述空间阻碍的伯胺是非天然存在的氨基酸或氨基酸衍生物(例如,1-氨基环己烷羧酸、羊毛硫氨酸(lanthanine)或茶氨酸)。在进一步实施方案中,所述空间阻碍的伯胺是环己胺、2-甲基丁基胺或聚氨基葡萄糖。
在其它实施方案中,提供了药物组合物,其包含药学上可接受的载体、利那洛肽、选自Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+的阳离子(例如,选自Zn2+、Mg2+或Ca2+的二价阳离子)和空间阻碍的伯胺。在一个实施方案中,所述阳离子是Ca2+。在另一个实施方案中,所述阳离子是Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+中的2种或3种的混合物(例如,Zn2+、Mg2+或Ca2+中的2种或3种的混合物)。在进一步实施方案中,所述药物组合物另外包含药学上可接受的粘合剂和/或药学上可接受的助流剂、润滑剂或作为助流剂和润滑剂二者的添加剂和/或抗氧化剂。在进一步实施方案中,所述空间阻碍的伯胺是氨基酸。在还进一步实施方案中,所述氨基酸是天然存在的氨基酸。在又进一步实施方案中,所述天然存在的氨基酸选自下面一组:组氨酸、苯丙氨酸、丙氨酸、谷氨酸、天冬氨酸、谷氨酰胺、亮氨酸、蛋氨酸、天冬酰胺、酪氨酸、苏氨酸、异亮氨酸、色氨酸、蛋氨酸和缬氨酸;更进一步,所述天然存在的氨基酸是亮氨酸、异亮氨酸、丙氨酸或蛋氨酸;在另一个实施方案中,所述天然存在的氨基酸是亮氨酸或蛋氨酸;更进一步,所述天然存在的氨基酸是亮氨酸。在另一个实施方案中,所述空间阻碍的伯胺可以是超过一种空间阻碍的伯胺的混合物。例如,所述空间阻碍的伯胺可以是2种或更多种空间阻碍的伯胺的混合物,例如,2种或更多种氨基酸的混合物。
在某些情况下,在应用于载体上的水性溶液中的阳离子:空间阻碍的伯胺:利那洛肽(例如,Ca2+:亮氨酸:利那洛肽)的摩尔比是5-100:5-50:1。可能希望,阳离子:空间阻碍的伯胺(例如,Ca2+:亮氨酸)的摩尔比等于或大于2:1(例如,在5:1和2:1之间)。因而,在某些情况下,应用于载体上的阳离子:空间阻碍的伯胺:利那洛肽(例如,Ca2+:亮氨酸:利那洛肽)的摩尔比是100:50:1、100:30:1、80:40:1、80:30:1、80:20:1、60:30:1、60:20:1、50:30:1、50:20:1、40:20:1、20:20:1、10:10:1、10:5:1或5:10:1。当在应用于载体上的利那洛肽溶液中存在粘合剂(例如,甲基纤维素)时,它可以以0.5%-2.5%(按重量计算)(例如,0.7%-1.7%或0.7%-1%或1.5%或0.7%)存在。
应用于给定重量的填充剂(例如,微晶纤维素)上的利那洛肽的重量可以在约0.02:100至约2.67:100之间变化。因而,可以将约0.05mg至约6.0mg利那洛肽应用于225mg填充剂。在进一步实施方案中,应用于给定重量的填充剂上的利那洛肽的重量是约0.05mg至约2.0mg利那洛肽(例如,对于225mg填充剂,是0.1、0.2、0.3.0.4、0.5、0.6、0.7mg肽)。
在不同的实施方案中:所述空间阻碍的伯胺是氨基酸(例如,天然存在的氨基酸,或选自下述的天然存在的氨基酸:组氨酸、苯丙氨酸、丙氨酸、谷氨酸、天冬氨酸、谷氨酰胺、蛋氨酸、天冬酰胺、酪氨酸、苏氨酸、亮氨酸、异亮氨酸、色氨酸或缬氨酸)。在其它情况下,所述空间阻碍的伯胺是非天然存在的氨基酸或氨基酸衍生物(例如,羊毛硫氨酸、茶氨酸或1-氨基环己烷)。在其它情况下,所述空间阻碍的伯胺是氨基糖(例如,聚氨基葡萄糖或葡糖胺)。
在某些情况下,空间阻碍的伯胺具有式:其中R1、R2和R3独立地选自:H;-C(O)OH;C1-C6烷基,其任选地被-CO2H、-CONH2或5-10元芳基或杂芳基取代;C1-C6烷氧基烷基;或C1-C6硫代烷氧基烷基,其中上述烷基或芳基中的任一个可以被卤素或–NH2单或多取代,且条件是,R1、R2和R3中不超过2个是H。在进一步实施方案中,R1、R2和R3中不超过1个是H。
本文使用的术语“烷基”表示饱和的直链的或支链单价烃基。除非另有说明,烷基含有1-20个碳原子(例如,1-20个碳原子、1-10个碳原子、1-8个碳原子、1-6个碳原子、1-4个碳原子或1-3个碳原子)。烷基的实例包括、但不限于:甲基、乙基、正丙基、异丙基、正丁基、异丁基、仲丁基、叔丁基、戊基、己基、庚基、辛基等。
术语Cn-m“烷氧基烷基”和Cn-m“硫代烷氧基烷基”是指被一个或多个烷氧基或硫代烷氧基(视情况而定)取代的烷基,其中烷基和烷氧基的组合的碳总数、或烷基和硫代烷氧基的组合的碳总数(视情况而定)是在n和m的值之间。例如,C4-6烷氧基烷基具有分在烷基和烷氧基部分中的共4-6个碳;例如它可以是CH2OCH2CH2CH3、
CH2CH2OCH2CH3或CH2CH2CH2OCH3。
当单独地或作为更大部分的一部分使用时,本文使用的术语“芳基”(如在“芳基环”或“芳基基团”中)表示这样的碳环系统,其中该系统中的至少一个环是芳族的,且与分子其它部分具有单个连接点。除非另有说明,芳基可以是单环的、双环的或三环的,且含有6-18个环成员。芳基环的实例包括、但不限于:苯基、萘基、茚满基、茚基、四氢萘、芴基和蒽基。
当单独地或作为更大部分的一部分如在“杂芳烷基”或“杂芳基烷氧基”中使用时,术语“杂芳基”(或“杂芳族的”或“杂芳基团”或“芳族杂环”)表示这样的环系统,其中该系统中的至少一个环是芳族的,且含有一个或多个杂原子,其中该系统中的每个环含有3-7个环成员,且与分子其它部分具有单个连接点。除非另有说明,杂芳基环系统可以是单环的、双环的或三环的,且具有共5-14个环成员。在一个实施方案中,杂芳基系统中的所有环是芳族的。在该定义中也包括这样的杂芳基基团,其中杂芳基环与一个或多个芳族或非芳族碳环或杂环或其组合稠合,只要所述基团(radical)或连接点是在杂芳基环中。例如,本文使用的双环6,5杂芳族系统是与第二个5元环稠合的6元杂芳族环,其中所述基团或连接点是在6元环上。
杂芳基环包括、但不限于下述单环:2-呋喃基、3-呋喃基、N-咪唑基、2-咪唑基、4-咪唑基、5-咪唑基、3-异唑基、4-异唑基、5-异唑基、2-唑基、4-唑基、5-唑基、N-吡咯基、2-吡咯基、3-吡咯基、2-吡啶基、3-吡啶基、4-吡啶基、2-嘧啶基、4-嘧啶基、5-嘧啶基、哒嗪基(例如,3-哒嗪基)、2-噻唑基、4-噻唑基、5-噻唑基、四唑基(例如,5-四唑基)、三唑基(例如,2-三唑基和5-三唑基)、2-噻吩基、3-噻吩基、吡唑基(例如,2-吡唑基)、异噻唑基、1,2,3-二唑基、1,2,5-二唑基、1,2,4-二唑基、1,2,3-三唑基、1,2,3-噻二唑基、1,3,4-噻二唑基、1,2,5-噻二唑基、吡嗪基、1,3,5-三嗪基;和下述双环:苯并咪唑基、苯并呋喃基、苯并噻吩基、苯并吡嗪基、苯并吡喃酮基(pyranonyl)、吲哚基(例如,2-吲哚基)、嘌呤基、喹啉基(例如,2-喹啉基、3-喹啉基、4-喹啉基)和异喹啉基(例如,1-异喹啉基、3-异喹啉基或4-异喹啉基)。
在不同的情况下:所述抗氧化剂选自BHA(丁羟茴醚)、BHT(丁羟甲苯)、维生素E、没食子酸丙酯、抗坏血酸和其盐或酯、生育酚和其酯、α-硫辛酸、β-胡萝卜素;所述药学上可接受的粘合剂是聚乙烯醇或聚乙烯吡咯烷酮;所述药学上可接受的粘合剂选自:淀粉(例如,玉米淀粉、预胶化的马铃薯淀粉、米淀粉、小麦淀粉和淀粉羟乙酸钠)、麦芽糊精或纤维素醚(例如,甲基纤维素、乙基纤维素、羧甲基纤维素、羟乙基纤维素、羟乙基甲基纤维素、羟丙基纤维素和羟丙基甲基纤维素);所述药学上可接受的填充剂是纤维素(例如,微细纤维素或微晶纤维素诸如Celphere CP-305或Avicel);所述药学上可接受的填充剂是糖或糖醇(例如,甘露醇、异麦芽酮糖醇、山梨醇、右旋糖、木糖醇、蔗糖和乳糖);所述填充剂包含具有50μm至1000μm的平均直径的颗粒;所述润滑剂和/或助流剂选自:滑石粉、亮氨酸、硬脂酸镁、硬脂酸和聚乙烯醇;和所述润滑剂和/或助流剂选自:硬脂酸钙、矿物油、植物油、聚乙二醇(PEG;例如,在室温是液体或固体的PEG)、苯甲酸钠和月桂基硫酸钠。
在某些情况下,在制备所述制剂的方法中使用的利那洛肽溶液具有低于7的pH(例如,1至3的pH,或约1.5至约2.5的pH)。可以用例如磷酸调节pH。在某些情况下,将溶液缓冲处理。可以使用不同的药学上可接受的缓冲剂(例如,磷酸盐缓冲剂)。
在某些情况下,在制备所述制剂的方法中使用的利那洛肽溶液包含阳离子(例如,CaCl2)和空间阻碍的伯胺(例如,亮氨酸)二者。
在某些情况下,所述利那洛肽溶液包含CaCl2和亮氨酸;所述粘合剂是甲基纤维素;所述填充剂是微晶纤维素;所述助流剂和/或润滑剂包含滑石粉或亮氨酸。
也提供了通过本文所述的任意方法制备的药物组合物。
在另一个方面,公开了药物组合物,其包含药学上可接受的载体、利那洛肽和一种或多种选自下述的试剂:(i)选自Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+的阳离子,或(ii)空间阻碍的伯胺。在有些实施方案中,所述药物组合物包含至少一种阳离子和至少一种空间阻碍的伯胺。
也描述了使用药物组合物治疗多种胃肠道障碍的方法。
附图说明
图1显示了通过HPLC分析利那洛肽的一个实例,其中“氧化”表示利那洛肽氧化产物,“甲醛亚胺”表示利那洛肽甲醛亚胺产物,且“水解”表示利那洛肽水解产物。
该图作为实例提供,无意限制本发明的范围。
具体实施方式
含有利那洛肽的口服组合物可以用于治疗多种胃肠道障碍。在不同的实施方案中,患者遭受胃肠道障碍;患者遭受选自下述的障碍:胃肠活动障碍、慢性肠假性梗阻、结肠假性梗阻、克罗恩病、十二指肠胃返流、消化不良、功能性消化不良、无溃疡性消化不良、功能性胃肠道障碍、功能性胃灼热、胃食管回流病(GERD)、胃肌轻瘫、肠易激综合征、手术后肠梗阻、溃疡性结肠炎、慢性便秘、便秘、与便秘有关的疼痛和与便秘有关的障碍和病症(例如与使用阿片剂镇痛药有关的便秘、手术后便秘和与神经病障碍以及本文所述的其它病症和障碍有关的便秘);患者遭受胃肠活动障碍、慢性肠假性梗阻、结肠假性梗阻、克罗恩病、十二指肠胃返流、消化不良、功能性消化不良、无溃疡性消化不良、功能性胃肠道病症、功能性胃灼热、胃食管回流病(GERD)、胃肌轻瘫、炎性肠病、肠易激综合征(例如腹泻-突出的肠易激综合征(d-IBS)、便秘-突出的肠易激综合征(c-IBS)和/或交替肠易激综合征(a-IBS))、手术后肠梗阻、溃疡性结肠炎、慢性便秘、便秘、与便秘有关的疼痛和与便秘有关的障碍和病症(例如与使用阿片剂镇痛药有关的便秘、手术后便秘和与神经病障碍以及本文所述的其它病症和障碍有关的便秘);患者已经根据Rome标准(例如Rome II)被诊断出功能性胃肠道病症,患者已经根据Rome标准(例如Rome II)被诊断出肠易激综合征(例如(例如腹泻突出的-IBS、便秘突出的-IBS和/或交替-IBS)。
对于成年人,利那洛肽的剂量范围通常是每天口服25μg至6mg。在进一步实施方案中,剂量范围是每天口服25μg至2mg。在有些实施方案中,成年人的剂量范围是每天口服50μg至1mg(例如,50μg、67.5μg、100μg、133μg、150μg、200μg、250μg、266μg、300μg、350μg、400μg、450μg、500μg、550μg、600μg、650μg、700μg、750μg、800μg、850μg、900μg、950μg或1mg)。在进一步实施方案中,剂量范围是每天口服100μg至600μg。在其它实施方案中,剂量是每天口服50μg、67.5μg、100μg、133μg、150μg、200μg、266μg、300μg、400μg、500μg或600μg利那洛肽。在一个实施方案中,所述利那洛肽组合物提供在分散的单位、单位剂型(例如,片剂、胶囊、药囊)中,其在这样的剂量或以多个这样的剂量是有效的。在某些实施方案中,单位剂型和日剂量是相当的。在不同的实施方案中,在一天的任意时间饭后(with food),在一天的任意时间饭前(without food),空腹过夜后饭后(例如早餐后),施用单位剂型。在不同的实施方案中,单位剂型每天施用1次、每天2次或每天3次。单位剂型可以任选地包含其它添加剂。在有些实施方案中,1、2或3个单位剂型含有日口服剂量的利那洛肽。施用给患者的化合物的精确量属于主治医师的职责。但是,采用的剂量取决于许多因素,包括患者的年龄和性别、待治疗的具体障碍和它的严重性。
在一个实施方案中,提供了在有此需要的成年患者中治疗具有便秘的肠易激综合征(IBS-c)的方法,所述方法包括,每天一次给所述患者施用有效量的本文所述的药物组合物。在不同的实施方案中,所述药物组合物包含133μg或266μg利那洛肽/单位剂量/天。在其它实施方案中,所述药物组合物施用至少1天、2天、3天、4天、5天、6天、1周、2周、3周、4周或更长的时段。在有些实施方案中,使用利那洛肽组合物的治疗会改善至少一种选自下述的症状:腹痛减轻、一周内完全自发排便(CSBM)次数增加、一周内自发排便(SBM)次数增加、大便稠度提高、使劲减少、腹部不适减少、胃气胀减轻或IBS-c症状严重性降低。
在一个实施方案中,提供了在有此需要的成年患者中治疗慢性便秘的方法,所述方法包括,每天一次给所述患者施用有效量的本文所述的药物组合物。在不同的实施方案中,所述药物组合物包含133μg或266μg利那洛肽/单位剂量/天。在其它实施方案中,所述药物组合物施用至少1天、2天、3天、4天、5天、6天、1周、2周、3周、4周或更长的时段。在有些实施方案中,使用利那洛肽组合物的治疗会改善至少一种选自下述的症状:一周内完全自发排便(CSBM)次数增加、一周内自发排便(SBM)次数增加、大便稠度提高、使劲减少、腹部不适减少、胃气胀减轻或便秘严重性降低。
通过7-点Bristol粪便形式量表(BSFS)(1=硬块,2=凹凸不平的香肠状物,3=有裂缝的香肠状物,4=光滑的香肠状物,5=软块,6=糊状,7=水样),可以监测每次排便(BM)的大便稠度。通过7-点排便容易度量表(1=人工嵌塞解除/需要灌肠剂,2=重度使劲,3=中等使劲,4=轻度使劲,5=不使劲,6=急迫,7=失禁),可以监测使劲。通过在SBM之后的完全排空感觉(是/否),可以测量CSBM。使用例如5-点顺序量表(1=无,2=轻度,3=中等,4=严重,5=非常严重),可以测量腹部不适、胃气胀和便秘的严重性。
本发明的阳离子可以作为药学上可接受的盐来提供,即,具有适当抗衡离子的阳离子。可以用于本发明中的药学上可接受的盐的实例包括、但不限于:醋酸镁、氯化镁、磷酸镁、硫酸镁、醋酸钙、氯化钙、磷酸钙、硫酸钙、乙酸锌、氯化锌、磷酸锌、硫酸锌、醋酸锰、氯化锰、磷酸锰、硫酸锰、乙酸钾、氯化钾、磷酸钾、硫酸钾、乙酸钠、氯化钠、磷酸钠、硫酸钠、醋酸铝、氯化铝、磷酸铝或硫酸铝。在有些实施方案中,所述药学上可接受的盐包括氯化钙、碳酸钙、醋酸钙、氯化镁、醋酸镁、乙酸锌和氯化锌。在进一步实施方案中,可以使用的药学上可接受的盐是氯化钙、氯化镁和乙酸锌。
本文使用的术语“粘合剂”表示可以用于实践本发明的任意药学上可接受的粘合剂。药学上可接受的粘合剂的实例包括、但不限于:淀粉(例如,玉米淀粉、马铃薯淀粉和预胶化的淀粉(例如,淀粉和淀粉1500(由Colorcon、Ltd.销售)和其它淀粉)、麦芽糊精、明胶、天然的和合成的树胶诸如阿拉伯胶、粉状黄蓍胶、瓜尔胶、纤维素和它的衍生物(例如,甲基纤维素、羟乙基纤维素、羟乙基甲基纤维素、羟丙基纤维素和羟丙基甲基纤维素(羟丙甲纤维素)、乙基纤维素、醋酸纤维素、羧甲基纤维素钙、羧甲基纤维素钠、羧甲基纤维素、微晶纤维素(例如AVICELTM,例如,AVICEL-PH-101TM、-103TM和-105TM,由FMCCorporation,Marcus Hook,PA,USA销售))、聚乙烯醇、聚乙烯吡咯烷酮(例如,聚乙烯吡咯烷酮K30)和其混合物。
本文使用的术语“填充剂”表示可以用于实践本发明的任意药学上可接受的填充剂。药学上可接受的填充剂的实例包括、但不限于:滑石粉、碳酸钙(例如,颗粒或粉末)、磷酸氢钙、磷酸三钙、硫酸钙(例如,颗粒或粉末)、微晶纤维素(例如,Avicel PH101或Celphere CP-305)、粉状纤维素、葡聚糖结合剂(dextrate)、高岭土、甘露醇、硅酸、山梨醇、淀粉(例如,淀粉1500)、预胶化的淀粉、乳糖、葡萄糖、果糖、半乳糖、海藻糖、蔗糖、麦芽糖、异麦芽酮糖醇、棉子糖、麦芽糖醇、松三糖、水苏糖、拉克替醇、palatinite、木糖醇、肌醇及其混合物。
特别用于用利那洛肽包被的药学上可接受的填充剂的实例包括、但不限于:滑石粉、微晶纤维素(例如,Avicel PH101或Celphere CP-305)、粉状纤维素、葡聚糖结合剂、高岭土、甘露醇、硅酸、山梨醇、淀粉、预胶化的淀粉、乳糖、葡萄糖、果糖、半乳糖、海藻糖、蔗糖、麦芽糖、异麦芽酮糖醇、磷酸氢钙、棉子糖、麦芽糖醇、松三糖、水苏糖、拉克替醇、palatinite、木糖醇、甘露醇、肌醇及其混合物。
本文使用的术语“添加剂”表示任意药学上可接受的添加剂。药学上可接受的添加剂包括、但不限于:崩解剂、分散剂、润滑剂、助流剂、抗氧化剂、包衣剂、稀释剂、表面活性剂、矫味剂、湿润剂、吸收促进剂、控释剂、抗结块剂、抗微生物剂(例如,防腐剂)、着色剂、干燥剂、增塑剂和染料。
本文使用的“赋形剂”是任意药学上可接受的添加剂、填充剂、粘合剂或试剂。
本文使用的“纯化的利那洛肽”是大于或等于90%纯度、或者大于或等于95%纯度的利那洛肽或其药学上可接受的盐。在有些实施方案中,纯化在本文所述的方法和组合物中使用的利那洛肽。可以测量利那洛肽纯度,例如,通过利那洛肽的色谱纯度,其中使用反相HPLC,如实施例21所述。可以测定利那洛肽实验[w/w],例如,通过使用反相HPLC,并通过使用参比标准的外部校准进行定量,如实施例21所述。
在一个方面,所述药物组合物可以如下制备:通过将包含利那洛肽或其药学上可接受的盐的溶液喷雾在药学上可接受的填充剂上,以产生利那洛肽-包被的填充剂。在一个实施方案中,所述方法包括:(a)提供溶液,例如,水性溶液(“包衣溶液”),其包含:(i)利那洛肽或其药学上可接受的盐;(ii)选自Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+的阳离子和/或空间阻碍的伯胺(例如,亮氨酸)和,任选地,(iii)药学上可接受的粘合剂;和(b)将包衣溶液应用于药学上可接受的填充剂,以产生多肽-包被的填充剂(例如,通过用包衣溶液喷雾、混合或包被药学上可接受的填充剂)。所述方法可以任选地包括下述一项或多项:(i)混合多肽-包被的填充剂和药学上可接受的助流剂、药学上可接受的润滑剂或作为助流剂和润滑剂二者的药学上可接受的添加剂;(ii)混合多肽-包被的填充剂和未曾多肽-包被的填充剂,(iii)混合多肽-包被的填充剂和其它添加剂;以及(iv)将药学上可接受的包衣添加剂应用于多肽-包被的填充剂。最终的药物组合物可以放入胶囊(例如,明胶胶囊)中,或用于形成片剂。
在另一个实施方案中,通过喷雾干燥制备所述药物组合物,所述喷雾干燥是用于制备药物的微粒(例如,微胶囊或微球)的技术。喷雾干燥的肽通常在溶解后保留它们的生物活性,且可以具有有用的物理特征,包括均匀的粒度和球形。另外,通过喷雾干燥制备的微粒经常是自由流动的,这有助于药物生产过程,诸如形成片剂和填充胶囊。喷雾干燥过程也是有用的,因为它们可以容易地放大用于临床和商业生产。
因而,本公开内容表征了制备包含利那洛肽或其药学上可接受的盐的药物组合物的方法,所述方法包括:(a)提供溶液,例如,水性的或有机的溶液,其包含:(i)利那洛肽或其药学上可接受的盐;和(ii)选自Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+的阳离子和/或空间阻碍的伯胺(例如,亮氨酸);和(b)喷雾干燥含有利那洛肽的溶液,以生成微粒。含有利那洛肽的溶液可以任选地包括聚合物,诸如一种或多种本文所述的粘合剂、脂质或磷脂和/或填充剂,诸如甘露醇。所述方法可以任选地包括一个或多个如下的额外步骤:(i)混合所述利那洛肽微粒和药学上可接受的助流剂、药学上可接受的润滑剂或作为助流剂和润滑剂二者的药学上可接受的添加剂;(ii)混合微粒和填充剂,和/或(iii)混合微粒和其它添加剂。最终的药物组合物可以放入胶囊(例如,明胶胶囊)中,或用于形成片剂。
在其它实施方案中,如下制备所述药物组合物:通过喷雾冷冻干燥、超临界流体加工或将溶液冻干,例如,水性的或有机的溶液,所述溶液包含:(i)利那洛肽或其药学上可接受的盐;和(ii)选自Mg2+、Ca2+、Zn2+、Mn2+、K+、Na+或Al3+的阳离子和/或空间阻碍的伯胺(例如,亮氨酸)。
在有些实施方案中,以用于口服给药的固体形式提供所述利那洛肽组合物。这样的形式的实例包括、但不限于:片剂、药囊、丸剂、胶囊或散剂。在有些实施方案中,所述组合物可以用于产生单位剂型、例如,片剂、胶囊、药囊或丸剂。口服给药的组合物可以包括,例如,粘合剂,润滑剂,惰性稀释剂,润滑的、表面活性的或分散的添加剂,矫味添加剂和湿润剂。口服给药的制剂(诸如片剂)可以任选地被包衣或刻痕,且可以配制成提供其中的利那洛肽的持续的、延迟的或受控的释放。利那洛肽可以与其它药物共同施用或共同配制。在一个实施方案中,所述利那洛肽组合物可以与用于治疗胃肠道障碍的其它药物共同施用。所述利那洛肽组合物也可以用于治疗在胃肠道以外的障碍,诸如充血性心力衰竭和良性前列腺肥大。
所述组合物可以包括,例如,不同的额外溶剂、分散剂、包衣剂、吸收促进添加剂、控释添加剂和一种或多种惰性添加剂(它们包括,例如,淀粉、多元醇、造粒添加剂、微晶纤维素、稀释剂、润滑剂、粘合剂、崩解添加剂等)等。如果需要,通过标准的水性的或非水性的技术,可以给公开的组合物的片剂包衣。组合物也可以包括,例如,抗结块添加剂、防腐剂、甜味添加剂、着色剂、矫味剂、干燥剂、增塑剂、染料等。
合适的崩解剂包括,例如,琼脂、碳酸钙、微晶纤维素、交联羧甲基纤维素钠、交聚维酮、聚维酮、波拉克林钾、淀粉羟乙酸钠、马铃薯或木薯淀粉、其它淀粉、预胶化的淀粉、粘土、其它藻胶、其它纤维素、树胶及其混合物。
合适的润滑剂包括,例如,硬脂酸钙、硬脂酸镁、矿物油、轻质矿物油、甘油、山梨醇、甘露醇、聚乙二醇、其它二醇类、硬脂酸、月桂基硫酸钠、滑石粉、氢化的植物油(例如,花生油、棉籽油、葵花子油、芝麻油、橄榄油、玉米油和大豆油)、硬脂酸锌、油酸乙酯、月桂酸乙酯、琼脂、syloid硅胶(AEROSIL 200,W.R.Grace Co.,Baltimore,MD USA)、合成的二氧化硅的凝结的气雾剂(Evonik Degussa Co.,Plano,TX USA)、热解二氧化硅(CAB-O-SIL,CabotCo.,Boston,MA USA)及其混合物。
合适的助流剂包括,例如,亮氨酸、胶体二氧化硅、三硅酸镁、粉状纤维素、淀粉、滑石粉和磷酸钙。
合适的抗结块添加剂包括,例如,硅酸钙、硅酸镁、二氧化硅、胶体二氧化硅、滑石粉及其混合物。
可以用作例如利那洛肽组合物的防腐剂的合适的抗微生物添加剂包括,例如,苯扎氯铵、苄索氯铵、苯甲酸、苯甲醇、对羟基苯甲酸丁酯、西吡氯铵、甲酚、三氯叔丁醇、脱氢醋酸、对羟基苯甲酸乙酯、对羟基苯甲酸甲酯、苯酚、苯乙醇、苯氧乙醇、醋酸苯汞、硝酸苯汞、山梨酸钾、对羟基苯甲酸丙酯、苯甲酸钠、脱氢醋酸钠、丙酸钠、山梨酸、硫柳汞、thymo及其混合物。
合适的包衣添加剂包括,例如,羧甲基纤维素钠、醋酸邻苯二甲酸纤维素、乙基纤维素、明胶、药用釉料膜(glaze)、羟丙基纤维素、羟丙基甲基纤维素、羟丙基甲基纤维素邻苯二甲酸酯、甲基纤维素、聚乙二醇、聚醋酸乙烯邻苯二甲酸酯、紫胶、蔗糖、二氧化钛、巴西棕榈蜡、微晶蜡及其混合物。合适的保护性的包衣剂包括Aquacoat(例如Aquacoat乙基纤维素水分散体,15%w/w,FMC Biopolymer,ECD-30),Eudragit(例如Eudragit E PO PE-EL,Roehm Pharma Polymers)和欧巴代(例如欧巴代AMB分散体,20%w/w,Colorcon)。
在某些实施方案中,适用于利那洛肽组合物的添加剂包括蔗糖、滑石粉、硬脂酸镁、交聚维酮或BHA中的一种或多种。
在某些实施方案中,术语“95%”可以是95.0%,术语“90%”可以是90.0%,术语“10%”可以是10.0%,术语“9%”可以是9.0%,术语“8%”可以是8.0%,术语“7%”可以是7.0%,术语“6%”可以是6.0%,术语“5%”可以是5.0%,术语“4%”可以是4.0%,术语“3%”可以是3.0%,术语“2%”可以是2.0%,且术语“1%”可以是1.0%。
在某些实施方案中,所述利那洛肽组合物以单位剂型提供。在有些实施方案中,单位剂型是胶囊、片剂、药囊、丸剂或散剂。在一个这样的实施方案中,单位剂型是胶囊剂或片剂。这样的单位剂型可以被装在容器中,该容器例如,不限于,纸或卡纸盒、玻璃或塑料瓶或罐、可重新密封的袋(例如,用于容纳片剂的“重填”,以放入不同的容器)、或泡罩包,所述泡罩包含有单个剂量,用于根据治疗方案从该包压出。在单个包装中一起使用一个以上的容器以提供单一剂型,也是可行的。例如,可以将片剂或胶囊装在瓶子中,所述瓶子又装在盒子内。在有些实施方案中,将单位剂型在另外装有干燥剂的容器中提供。在进一步实施方案中,将单位剂型(例如,一定量片剂或胶囊)提供在装有干燥剂的容器(例如,瓶子、罐或可重新密封的袋)中。在进一步实施方案中,将装有单位剂型的容器与施用或剂量说明书一起包装。在某些实施方案中,利那洛肽组合物提供在药剂盒中。可以将本文所述的利那洛肽组合物和联合治疗剂包装为包括单个或多个剂量的2种或更多种药剂的药剂盒,它们各自单独地包装或配制,或组合地包装或配制单个或多个剂量的2种或更多种药剂。因而,利那洛肽组合物可以存在于第一个容器中,且药剂盒可以任选地包括在第二个容器中的一种或多种药剂。一个或多个容器放在包装内,且所述包装可以任选地包括施用或剂量说明书。
实施例
下面的实施例仅仅是本发明的例证,不应当解释为以任何方式限制本发明的范围,因为本领域技术人员在阅读本公开内容后,会明白本发明包括的许多变化和等同方案。
使用本领域已知的标准技术,例如,化学合成或重组表达,继之以使用标准技术的纯化,可以生产和纯化利那洛肽或其药学上可接受的盐。
制剂方案A
包衣溶液的制备:将大约32g至42g纯化水与盐酸混合,以产生pH在1.5至2.0的溶液。将一定量的阳离子(如果使用的话)加入溶液,以提供希望的浓度,并将溶液混合足够的时间,以生成澄清溶液。将一定量的空间阻碍的伯胺(如果使用的话)加入溶液,以提供希望的浓度,并将溶液混合足够的时间,以生成澄清溶液。然后加入其它添加剂,诸如抗氧化剂(如果需要的话)。测试溶液的pH,并在必要时加入盐酸,以生成pH在1.5至2.0的溶液。然后将粘合剂加入溶液,并然后将混合物搅拌足够的时间,以生成澄清溶液。将希望的量的利那洛肽加入溶液,并混合30-100分钟,以得到包衣溶液。
活性珠子的制备:将大约30-36g干燥的微晶纤维素珠子加入微型柱流化床包衣机(Mini Column Fluid Bed Coater)中。在包衣之前,使微晶纤维素珠子流态化,并加热。接着,将包衣溶液包被到珠子上。通过控制入口温度、喷雾速率、雾化压力和空气体积,将喷雾温度控制在24℃至55℃之间。在将所有包衣溶液包被到珠子上以后,干燥珠子。该过程的产品称作活性珠子。
具有保护性包衣的活性珠子的制备:将大约35g活性珠子加入微型柱流化床包衣机。在用Aquacoat(例如Aquacoat乙基纤维素水分散体,15%w/w,FMC Biopolymer,ECD-30),Eudragit(例如Eudragit E PO PE-EL,Roehm Pharma Polymers)和欧巴代(例如欧巴代AMB分散体,20%w/w,Colorcon)包衣之前,使活性珠子流态化,并加热。接着,将包衣溶液包被到珠子上。通过控制入口温度、喷雾速率、雾化压力和空气体积,将喷雾温度控制在24℃至55℃之间。在将所有包衣溶液包被到珠子上以后,干燥珠子。
制剂方案B
包衣溶液的制备:将大约8.3kg纯化水与盐酸混合,以产生pH在1.5至2.0的溶液。将一定量的阳离子(如果使用的话)加入溶液,以提供希望的浓度,并将溶液混合足够的时间,以生成澄清溶液。将一定量的空间阻碍的伯胺(如果使用的话)加入溶液,以提供希望的浓度,并将溶液混合足够的时间,以生成澄清溶液。然后加入其它添加剂,诸如抗氧化剂(如果需要的话)。然后将粘合剂加入溶液,并将溶液混合足够的时间,以生成澄清溶液。测试溶液的pH,并在必要时加入盐酸,以生成pH在1.5至2.0的溶液。这是溶液1。将大约8.3kg纯化水与盐酸混合,以产生pH在1.5至2.0的溶液。将希望的量的利那洛肽加入溶液,并混合10-30分钟。测试溶液的pH,并在必要时加入盐酸,以生成pH在1.5至2.0的溶液。这是溶液2。然后将溶液1和溶液2混合到一起。测试溶液的pH,并在必要时加入盐酸,以生成pH在1.5至2.0的溶液。这是包衣溶液。
活性珠子的制备:将大约24.19kg微晶纤维素珠子加入Glatt GPCG-30流化床的Wurster柱。使微晶纤维素珠子流态化,并加热到产品的温度45-47℃。接着,将包衣溶液包被到珠子上。通过控制入口温度、喷雾速率、雾化压力和空气体积,将产物喷雾温度控制在37℃至47℃。在将所有包衣溶液包被到珠子上以后,用37℃至47℃的产物干燥温度干燥珠子。该过程的产品称作活性珠子。
实施例1-15:利那洛肽制剂的制备
基本上如制剂方案A所述,生产实施例1-15的利那洛肽制剂,其中表1提供了阳离子、空间阻碍的伯胺、粘合剂、利那洛肽和珠子的量,而表2提供了包被珠子的条件:
表1
*“阳离子”表示在实施例中使用的盐包含的二价阳离子,“胺”表示空间阻碍的伯胺,[]表示阳离子和/或胺与利那洛肽的摩尔比。
**基于在为利那洛肽活性药物成分(API)的每个生产批次提供的分析证书上列出的肽含量和色谱纯度,确定在该实施例和所有以下实施例中的利那洛肽的量。
表2
实施例16:利那洛肽制剂的制备
基本上如制剂方案B所述,生产实施例16的利那洛肽制剂,其中表3提供了阳离子、空间阻碍的伯胺、粘合剂、利那洛肽和珠子的量,而表4提供了包被珠子的条件:
表3
表4
实施例17:利那洛肽制剂的制备
除了制剂含有22.96mg丁羟茴醚(BHA)以外,基本上如制剂方案A所述,生产实施例17的利那洛肽制剂,其中表5提供了阳离子、空间阻碍的伯胺、粘合剂、利那洛肽和珠子的量,而表6提供了涂覆珠子的条件。
表5
表6
实施例18:含有利那洛肽制剂的胶囊的制备
如实施例21所述,或通过其它等效方法,可以测量活性珠子上的利那洛肽含量。
为了形成适合口服给药的胶囊,使用适当量的活性珠子来填充明胶胶囊(例如,2号明胶胶囊)。适当量的活性珠子可以含有50μg至2mg利那洛肽/胶囊,在±5%范围内。在有些实施方案中,在活性珠子上的利那洛肽的适当量可以是50μg、67.5μg、100μg、133μg、150μg、200μg、266μg、300μg、400μg、500μg、600μg、700μg、800μg、900μg、1mg、2mg、4mg或6mg。在一个具体实施方案中,在活性珠子上的利那洛肽的适当量是67.5μg、100μg、133μg、150μg、200μg、266μg、300μg、400μg、500μg、600μg。在一个更具体的实施方案中,在活性珠子上的利那洛肽的适当量是每个胶囊67.5μg、133μg、150μg、266μg或300μg。
在另一个实施方案中,将用于填充预期数目的明胶胶囊的适当量的活性珠子放在容器中。如果需要,可以将一种或多种药学上可接受的填充剂或其它药学上可接受的添加剂加入容器中。在有些实施方案中,填充剂或添加剂是滑石粉、亮氨酸、微晶纤维素或甘露醇。混合容器的内容物,并使用混合物填充明胶胶囊,具有适当量的含有利那洛肽的活性珠子(例如,每个胶囊50μg至2mg利那洛肽,在±5%范围内)。
在一个替代实施方案中,使用适当量的活性珠子填充明胶胶囊,并将一种或多种药学上可接受的填充剂或其它药学上可接受的添加剂加入明胶胶囊中。
实施例19:含有利那洛肽制剂的胶囊的制备
包衣溶液的制备:首先,将41.98g纯化水与1.13g盐酸相混合,以产生pH在1.5至2.0的溶液。接着,将7.49g氯化钙二水合物和6.68g亮氨酸加入溶液中,然后将其混合30分钟,以生成澄清溶液。测试pH,并加入1.70g盐酸,以生成pH在1.5至2.0的溶液。接着,将13.27g羟丙甲纤维素(羟丙基甲基纤维素;Dow Chemical Company;Midland,MI)加入溶液,并将混合物搅拌60分钟,以得到澄清溶液。接着,将4.39g利那洛肽加入溶液,并混合90分钟。溶液的pH是1.73。这是包衣溶液。
活性珠子的制备:将674.5g微晶纤维素珠子(Celphere CP-305;Ashai KaseiCorporation(日本东京)加入Glatt GPCG-2流化床的Wurster柱。使微晶纤维素珠子流态化,并在60℃的产物温度加热30分钟。接着,将包衣溶液包被到珠子上。通过80℃的入口温度、5.0-11g/min的喷雾速率、2.0巴的雾化压力和40-50m3h的空气体积,将产物温度控制在45℃至49℃之间。在将所有包衣溶液包被到珠子上以后,用46.9℃至50.9℃的产物温度干燥珠子10分钟。该过程的产品称作活性珠子。
从如上所述制备的制剂提取的利那洛肽的反相液相色谱法证实,提取的利那洛肽和利那洛肽参比标准表现出相同的保留时间,且所述制剂过程结果没有引起纯度的显著变化。
为了形成胶囊,将49.50g活性珠子加入透明袋。接着,将筛过60目筛的0.25g亮氨酸加入该袋。系紧袋子,并混合125转,从而混合所有物质。接着,将筛过60目筛的0.25g滑石粉加入该袋。系紧袋子,并混合125转,从而混合所有物质。一旦混合所有物质后,使用混合物填充2号明胶胶囊,目标重量为227mg/胶囊,在±5%范围内。
实施例20:含有利那洛肽制剂的胶囊的制备
根据实施例16制备活性珠子。测试活性珠子的利那洛肽含量。基于活性珠子的测定,使用MG2Futura封装机,将适当量的活性珠子(96mg–123mg)填充进2号硬明胶胶囊,以得到300μg的利那洛肽浓度。
根据实施例15制备活性珠子。测试活性珠子的利那洛肽含量。基于活性珠子的测定,使用MG2Futura封装机,将适当量的活性珠子(48mg–62mg)填充进2号硬明胶胶囊,以得到150μg的利那洛肽浓度。
实施例21:利那洛肽含量和纯度的测量
使用具有Chemstation Rev A.09.03软件或等效软件的Agilent Series 1100 LC系统,通过反相梯度液相色谱法,可以测定利那洛肽含量和纯度,以及利那洛肽-相关物质的测量。使用YMC ProTM C18柱(尺寸:3.0x150mm,3.5um,Waters Corp.,Milford,MA)或等效柱,并维持在40℃。流动相A(MPA)由含有0.1%三氟醋酸的水组成,而流动相B(MPB)由95%乙腈:5%含有0.1%三氟醋酸的水组成。如下洗脱利那洛肽和它的相关物质:使用在28分钟内的0%至47%MPB的梯度,继之以在4分钟内升高至100%MPB,在100%MPB保持5分钟,以洗涤柱。通过在1分钟内恢复至0%MPB,继之以在100%MPA保持10分钟,重新平衡柱。流速是0.6mL/min,并用220nm紫外线进行检测。
如下制备用于分析的样品:通过将利那洛肽胶囊的内容物加入0.1N HCl中,得到20μg利那洛肽/mL的目标浓度。将100μL该溶液注射到柱上。
通过相对于类似地制备的外部利那洛肽标准品测定制备的样品中的利那洛肽浓度,测量利那洛肽含量。
在图1中显示了通过HPLC分析利那洛肽的一个实例,其中“氧化”表示利那洛肽氧化产物,“甲醛亚胺”表示利那洛肽甲醛亚胺产物,且“水解”表示利那洛肽水解产物。
实施例22:利那洛肽制剂稳定性试验
对于实施例1-15和17的制剂,给明胶胶囊填充大约225mg活性珠子。将5个填充的胶囊放入塑料瓶中。该瓶子装有1-2g干燥剂,并抽气密封(induction sealed)。将瓶子在40℃/75%RH储存6个月。
基本上如实施例21所述或通过等效方法,测量利那洛肽含量和纯度以及利那洛肽-相关物质的量。结果提供在表7中。
表7
对于实施例16的制剂,给明胶胶囊填充大约113mg总珠子。将35个填充的胶囊放入塑料瓶中。该瓶子装有2g干燥剂,并抽气密封。将瓶子在40℃/75%RH储存1个月。
基本上如实施例21所述或通过等效方法,测量利那洛肽含量和纯度以及利那洛肽-相关物质的量。结果提供在表8中。
表8
实施例23:利那洛肽水解产物的分离和制备
随着在7位的Asn转化成Asp(利那洛肽的编号在N-末端Cys从1开始),产生利那洛肽水解产物。它的结构如下所述:
使用标准的固相肽合成技术,已经独立地合成了用于证实身份的利那洛肽水解产物。还可以通过本领域已知的其它方法,制备利那洛肽水解产物,例如,通过使用色谱技术从利那洛肽制备物分离,或通过重组表达编码利那洛肽水解产物(Cys Cys Glu Tyr CysCys Asp Pro Ala Cys Thr Gly Cys Tyr)的核酸,任选地随后氧化半胱氨酸残基以形成二硫键。
实施例24:利那洛肽甲醛亚胺产物的分离和制备
随着经由甲醛-介导的反应向N-末端Cys(Cys1)添加亚胺,产生甲醛亚胺产物。提出的产物的结构如下所述:
通过使利那洛肽与甲醛(1:5摩尔比)在无水乙醇中在室温反应4天,已经独立地合成了用于证实身份的利那洛肽甲醛亚胺产物。还可以通过本领域已知的其它方法制备甲醛亚胺产物,例如,通过使用色谱技术从利那洛肽制备物分离,或通过化学肽合成或重组表达编码利那洛肽的核酸,随后如本文所述或通过本领域已知的其它方法甲酰化,任选地随后氧化半胱氨酸残基以形成二硫键。
实施例25:利那洛肽氧化产物的分离和制备
利那洛肽氧化产物具有1542.8的分子量。该氧化产物最可能随着单个氧原子添加到利那洛肽的6个半胱氨酰硫之一上而形成。下面描述了所述产物的一种可能的结构,尽管本领域技术人员会认识到,氧原子可以连接到其它5个硫中的任一个上:
为了支持该鉴别,通过使利那洛肽与过氧化氢(3%水溶液)在室温或40℃反应至多达24小时,已经生产了利那洛肽氧化产物。得到的产物富含了1-10%的氧化产物。还可以通过本领域已知的其它方法制备利那洛肽氧化产物,例如,通过使用色谱技术从利那洛肽制备物分离,或通过化学肽合成或重组表达编码利那洛肽的核酸,随后氧化半胱氨酸残基形成二硫键,随后使利那洛肽与过氧化氢或类似的氧化试剂反应,以形成利那洛肽氧化产物。
实施例26:利那洛肽片剂形成
流化床造粒
将利那洛肽、CaCl2、亮氨酸和聚乙烯吡咯烷酮(PVP)K30溶于0.0001N HCl中,以形成包衣溶液(参见表9)。将异麦芽酮糖醇装入流化床的碗中。在使异麦芽酮糖醇粉末流态化的同时,以~10g/min的速度,从上面喷洒药物溶液,产物温度为~40C,以用包衣溶液包被粉末。完成喷雾后,干燥利那洛肽颗粒30分钟,并卸掉产物。
表9
也使用磷酸二钙或Avicel作为流化床造粒的填充剂。
湿法制粒
称量利那洛肽,在搅拌下溶于250g 0.1N HCl(pH 1.7)中,以形成溶液1(参见表10)。称量CaCl2和亮氨酸,在搅拌下溶于100g 0.1N HCl中,以形成溶液2。将溶液1和溶液2在搅拌下混合到一起,以形成包衣溶液。将Avicel加入高切力制粒机的碗中。在500rpm混合下,将包衣溶液加入Avicel中。加入溶液结束后,混合颗粒,并切割1分钟。将得到的湿颗粒装入流化床的碗中,干燥15分钟,然后卸掉利那洛肽颗粒。
表10
在湿法制粒配方中,分别在60-100和30-50的范围内,调节CaCl2和亮氨酸与利那洛肽的摩尔比。另外,在一个实施例中加入蔗糖。参见表11。
表11
片剂制剂
将利那洛肽颗粒与下述赋形剂(参见表12)相混合,并压制成片剂,硬度为~4kp。
表12
基于上面的配方,也将异麦芽酮糖醇、淀粉1500或磷酸二钙用作片剂填充剂(参见表13)。
表13
在40℃和75%相对湿度储存2周后,在表13中所述的所有片剂表现出大于90%的利那洛肽试验值。
实施例27-53:利那洛肽制剂的制备
基本上如制剂方案A和实施例1-15所述,生产实施例27-53的利那洛肽制剂。利那洛肽包衣溶液含有0.7%粘合剂(w/v),并如实施例1-15所述,将包衣溶液喷雾到CelphereCP-305珠子上。表14提供了阳离子的类型、胺和/或其它赋形剂的类型以及它们相对于利那洛肽的摩尔比、以及使用的粘合剂的类型,而表15提供了包被珠子的条件:
表14
*“阳离子”表示在该实施例中使用的盐含有的阳离子,“胺”表示空间阻碍的伯胺,“摩尔比”表示阳离子:胺:利那洛肽:添加剂(如果使用)的摩尔比。
表15
对于实施例32(藻酸钙)、34(硬脂酸钙)和43(CaCl2:维生素E),在喷雾到珠子上的过程中,发生加工问题。因而,将包衣溶液与Celphere珠子一起混合,并在托盘上干燥珠子。
实施例54:利那洛肽制剂稳定性试验
对于实施例27-53的制剂,给明胶胶囊填充大约225mg活性珠子(600μg利那洛肽/胶囊)。将5个填充的胶囊放入塑料瓶中。所述瓶子含有1g干燥剂,并抽气密封。将瓶子在40℃/75%RH储存3个月或6个月。
基本上如实施例21所述或通过等效方法,测量利那洛肽含量(μg/mg)和色谱纯度百分比(%CP)。结果提供在表16A(3个月稳定性)或表16B(6个月稳定性)中。
表16A
*试验[w/w,最初的%]的值的差异性反映了在小规模生产的这些胶囊批次对含量均匀度的不完美控制。
据信,对于实施例32、34和43(参见上面)而言,在加工过程中遇到的困难和得到的改进的加工操作可以解释在这些样品中观察到的更低的稳定性。
表16B
对于实施例27-53,在6个月时间点的色谱纯度值显得非典型的低,特别是相对于这些样品的3个月时间点。通过与作为内部参比实验的实施例27和实施例31进行对比,可以建立稳定或失稳效应的相对趋势,所述内部参比实验的色谱纯度值比在已经进行的其它研究中一致地观察到的低大约6-8%(参见,例如,实施例2和9)。在表16A中提供的相同制剂的3个月数据显示出更典型的色谱纯度值。因而,在6个月的低色谱纯度值可能是由于对于这些具体贮存条件而言在6个月时的不足的干燥能力。该假设得到观察到的杂质峰的支持,所述杂质峰是暴露于水分的指示指标。
实施例55:在25℃/60%RH下24个月的利那洛肽制剂稳定性试验
对于实施例8-15和17的制剂,给明胶胶囊填充大约225mg活性珠子。将5个填充的胶囊放入塑料瓶中。所述瓶子含有1g干燥剂,并抽气密封。将瓶子在25℃/60%RH下储存24个月。
基本上如实施例21所述或通过等效方法,测量利那洛肽含量和纯度以及利那洛肽-相关物质的量。结果提供在表17中。
表17
1)关于含有额外的Aquacoat保护性包衣(Aquacoat乙基纤维素水分散体,15%w/w,FMC Biopolymer,ECD-30)的实施例10。
2)关于含有额外的欧巴代保护性包衣(欧巴代AMB分散体,20%w/w,Colorcon)的实施例10。
3)关于含有额外的Eudragit保护性包衣(Eudragit E PO,Degussa,Roehm PharmaPolymers;SLS,硬脂酸)的实施例10。
实施例56:利那洛肽片剂制剂和稳定性试验
使用表18所述的试剂,基本上如实施例26所述,通过流化床造粒制备活性利那洛肽颗粒。将利那洛肽颗粒与表19所述的赋形剂相混合,并压制成片剂,硬度为~4kp。
将35片包装进装有5g干燥剂的60cc瓶子,并在40℃/75%RH下储存至多达3个月,或在30℃/65%RH下储存至多达3个月。
基本上如实施例21所述或通过等效方法,测量利那洛肽含量和纯度以及利那洛肽-相关物质的量。结果提供在表20中。
表18
成分 | 功能 | 颗粒,150μg利那洛肽/53.7mg颗粒 |
利那洛肽 | API | 0.15mg |
甘露醇,USP | 颗粒填充剂 | 50mg |
亮氨酸,USP | 稳定剂 | 0.64mg |
CaCl2·2H2O,USP | 稳定剂 | 0.72mg |
PVPK30,USP | 粘合剂 | 2.2mg |
HCl溶液(pH2.5) | -- | -- |
表19
表20
条件 | 时间 | 试验的变化% | 总降解 |
40℃/75%RH | 最初 | 100 | 2.27 |
40℃/75%RH | 1个月 | 96.2 | 2.09 |
40℃/75%RH | 2个月 | 102 | 2.15 |
40℃/75%RH | 3个月 | 99.5 | 1.52 |
30℃/65%RH | 3个月 | 100.1 | 1.19 |
实施例57:利那洛肽胶囊制剂
基本上如实施例16所述,生产实施例57的利那洛肽制剂。表21提供了完整利那洛肽珠子药物包衣溶液的包衣溶液成分和它们的理论重量(mg/g)和(kg/批)。表22提供了用于制备利那洛肽活性珠子的成分和理论重量(mg/g)和(kg/批)。基本上如实施例20所述,将利那洛肽制剂包裹在硬明胶胶囊2号(重量61mg)中。150μg利那洛肽胶囊含有56mg利那洛肽珠子(600μg利那洛肽/225mg珠子),而300μg利那洛肽胶囊含有113mg利那洛肽珠子(600μg利那洛肽/225mg珠子)。
表21
表22
Claims (10)
1.一种包含利那洛肽和药学上可接受的赋形剂的药物组合物,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述药物组合物18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述药物组合物6个月后,所述利那洛肽的色谱纯度降低了小于10%。
2.根据权利要求1的药物组合物,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述药物组合物18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述药物组合物6个月后,所述利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%或4%。
3.一种包含利那洛肽和药学上可接受的赋形剂的药物组合物的单位剂型,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述单位剂型18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述单位剂型6个月后,所述利那洛肽的色谱纯度降低了小于10%。
4.根据权利要求3的单位剂型,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述单位剂型18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述单位剂型6个月后,所述利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%或4%。
5.一种密封容器,其装有包含利那洛肽和药学上可接受的赋形剂的药物组合物的多个单位剂型,其中(a)在25℃在60%相对湿度储存装有干燥剂的所述密封容器18个月后,或(b)在40℃在75%相对湿度储存装有干燥剂的所述密封容器6个月后,所述利那洛肽的色谱纯度降低了小于10%。
6.根据权利要求5的密封容器,其中(a)在25℃在60%相对湿度储存装有干燥剂的所述密封容器18个月后,或(b)在40℃在75%相对湿度储存装有干燥剂的所述密封容器6个月后,所述利那洛肽的色谱纯度降低了小于9%、8%、7%、6%、5%或4%。
7.一种包含利那洛肽和药学上可接受的赋形剂的药物组合物,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述药物组合物18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述药物组合物6个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。
8.根据权利要求7的药物组合物,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述药物组合物18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述药物组合物6个月后,所述利那洛肽的测定值降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。
9.一种包含利那洛肽和药学上可接受的赋形剂的药物组合物的单位剂型,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述单位剂型18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述单位剂型6个月后,基于重量/重量测得的利那洛肽的测定值降低了小于10%。
10.根据权利要求9的单位剂型,其中(a)在装有干燥剂的密封容器中在25℃在60%相对湿度储存所述单位剂型18个月后,或(b)在装有干燥剂的密封容器中在40℃在75%相对湿度储存所述单位剂型6个月后,所述利那洛肽的测定值降低了小于9%、8%、7%、6%、5%、4%、3%、2%或1%。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8942208P | 2008-08-15 | 2008-08-15 | |
US61/089422 | 2008-08-15 | ||
US27333209P | 2009-08-03 | 2009-08-03 | |
US61/273332 | 2009-08-03 | ||
US23172509P | 2009-08-06 | 2009-08-06 | |
US61/231725 | 2009-08-06 | ||
CN200980140931.9A CN102186490B (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980140931.9A Division CN102186490B (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109010254A true CN109010254A (zh) | 2018-12-18 |
Family
ID=41666602
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210243774.1A Pending CN114668711A (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
CN201810378167.XA Pending CN109010254A (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
CN201510363805.7A Pending CN105168114A (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
CN200980140931.9A Active CN102186490B (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
CN202311333813.8A Pending CN117530912A (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210243774.1A Pending CN114668711A (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510363805.7A Pending CN105168114A (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
CN200980140931.9A Active CN102186490B (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
CN202311333813.8A Pending CN117530912A (zh) | 2008-08-15 | 2009-08-14 | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 |
Country Status (31)
Country | Link |
---|---|
US (7) | US8802628B2 (zh) |
EP (2) | EP2328601B1 (zh) |
JP (9) | JP5770629B2 (zh) |
KR (11) | KR101704832B1 (zh) |
CN (5) | CN114668711A (zh) |
AU (1) | AU2009282446B2 (zh) |
BR (1) | BRPI0917807A2 (zh) |
CA (1) | CA2732892C (zh) |
CL (1) | CL2011000314A1 (zh) |
CO (1) | CO6351746A2 (zh) |
CY (1) | CY1122801T1 (zh) |
DK (1) | DK2328601T3 (zh) |
EA (1) | EA201170337A1 (zh) |
ES (1) | ES2785980T3 (zh) |
GE (1) | GEP20156209B (zh) |
HK (2) | HK1161978A1 (zh) |
HR (1) | HRP20200512T1 (zh) |
HU (1) | HUE049023T2 (zh) |
IL (1) | IL211028A (zh) |
LT (1) | LT2328601T (zh) |
MX (3) | MX2011001620A (zh) |
NZ (1) | NZ591713A (zh) |
PE (2) | PE20151205A1 (zh) |
PH (1) | PH12015501579B1 (zh) |
PL (1) | PL2328601T3 (zh) |
PT (1) | PT2328601T (zh) |
RS (1) | RS60101B1 (zh) |
SG (1) | SG193801A1 (zh) |
SI (1) | SI2328601T1 (zh) |
WO (1) | WO2010019266A2 (zh) |
ZA (1) | ZA201101523B (zh) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2328601T1 (sl) | 2008-08-15 | 2020-08-31 | Ironwood Pharmaceuticals, Inc. | Linaklotid vsebujoče formulacije za oralno dajanje |
JP5964589B2 (ja) | 2008-12-03 | 2016-08-03 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcアゴニストの製剤およびその使用方法 |
JP2013501071A (ja) * | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | リナクロチドを含む処方物 |
RU2012109415A (ru) * | 2009-08-13 | 2013-09-20 | Айронвуд Фармасьютикалз, Инк. | Способ модуляции фармакодинамического эффекта перорально вводимых агонистов рецептора гуанилатциклазы |
CA2780337A1 (en) * | 2009-11-03 | 2011-05-12 | Ironwood Pharmaceuticals, Inc. | Linaclotide for the treatment of chronic constipation |
CN102812038B (zh) * | 2009-11-09 | 2016-05-18 | 硬木药品公司 | 胃肠道病症的治疗 |
EP2509992B1 (en) | 2009-12-07 | 2015-10-14 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
PL2536742T3 (pl) | 2010-02-17 | 2017-11-30 | Ironwood Pharmaceuticals, Inc. | Leczenie zaburzeń żołądkowo-jelitowych |
JP5921545B2 (ja) | 2010-08-11 | 2016-05-24 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | リナクロチドの安定な製剤 |
CN103702678A (zh) * | 2010-09-11 | 2014-04-02 | 硬木药品公司 | 便秘型肠易激综合征的治疗 |
EP2621509A4 (en) | 2010-09-15 | 2016-08-03 | Synergy Pharmaceuticals Inc | PREPARATIONS OF GUANYLATE CYCLASE-C AGONISTS AND METHODS OF USE |
US9616097B2 (en) * | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012155114A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Peptides derived from uroguanylin and their use in gastrointestinal disorders |
CA2835624A1 (en) | 2011-05-11 | 2012-11-15 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
WO2012170766A1 (en) | 2011-06-08 | 2012-12-13 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
US9617305B2 (en) | 2011-06-08 | 2017-04-11 | Ironwood Pharmaceuticals, Inc. | Treatments for gastrointestinal disorders |
PL2776055T3 (pl) | 2011-08-17 | 2017-06-30 | Ironwood Pharmaceuticals, Inc. | Sposoby leczenia zaburzeń żołądkowo-jelitowych |
WO2013047795A1 (ja) * | 2011-09-30 | 2013-04-04 | アステラス製薬株式会社 | 粒子状医薬組成物 |
US20140018307A1 (en) * | 2012-07-12 | 2014-01-16 | Forest Laboratories Holdings Ltd. | Linaclotide compositions |
US20150361139A1 (en) * | 2013-01-30 | 2015-12-17 | Sandoz Ag | Crystalline form of linaclotide |
MX2016001714A (es) | 2013-08-09 | 2016-10-03 | Ardelyx Inc | Compuestos y metodos para inhibir el transporte de fosfato. |
UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
WO2016024291A1 (en) * | 2014-08-11 | 2016-02-18 | Sun Pharmaceutical Industries Ltd. | Linaclotide stable composition |
ES2630106T3 (es) * | 2014-10-07 | 2017-08-18 | Cyprumed Gmbh | Formulaciones farmacéuticas para la administración oral de fármacos peptídicos o proteicos |
CN104569245A (zh) * | 2014-12-08 | 2015-04-29 | 江苏泰洁检测技术有限公司 | 一种工作场所脂肪族胺类中环己胺浓度测定方法 |
WO2016125064A1 (en) * | 2015-02-02 | 2016-08-11 | Aurobindo Pharma Ltd | Stable compositions comprising linaclotide |
ES2868873T3 (es) * | 2015-06-05 | 2021-10-22 | Ironwood Pharmaceuticals Inc | Formulaciones de liberación modificada o dirigida de linaclotida |
WO2017060500A1 (en) | 2015-10-07 | 2017-04-13 | Cyprumed Gmbh | Pharmaceutical formulations for the oral delivery of peptide drugs |
BR112019012689A2 (pt) | 2016-12-21 | 2019-11-19 | Ironwood Pharmaceuticals Inc | métodos de tratamento da síndrome do intestino irritável com formulações de linaclotide modificada ou de liberação prolongada |
CN107669700A (zh) * | 2017-09-14 | 2018-02-09 | 湖南晓林生物科技发展有限公司 | 一种治疗溃疡性结肠炎的药物及其制备方法 |
BR112021000201A2 (pt) | 2018-07-09 | 2021-08-10 | Abbott Laboratories Gmbh | composição farmacêutica contendo um peptídeo |
JP2022533251A (ja) | 2019-05-21 | 2022-07-21 | アルデリックス, インコーポレイテッド | 患者において血清リン酸塩を低下させるための組み合わせ |
CN112121021B (zh) * | 2019-06-24 | 2022-03-25 | 深圳翰宇药业股份有限公司 | 一种含利那洛肽的药物组合物及其制备方法 |
WO2022002369A1 (en) * | 2020-06-30 | 2022-01-06 | Ocvirk Soeren | Pharmaceutical composition comprising a combination of a guanylate cyclase c (gucy2c) agonist and a short-chain fatty acid or prodrug thereof |
CN113616616A (zh) * | 2021-09-07 | 2021-11-09 | 四川国为制药有限公司 | 一种利那洛肽胶囊制剂及其制备方法 |
US20230106943A1 (en) * | 2021-09-17 | 2023-04-06 | Peptilogics, Inc. | Engineered antimicrobial peptides and usage thereof |
CN114632141B (zh) * | 2022-04-19 | 2023-08-01 | 苏州中化药品工业有限公司 | 一种含利那洛肽的药物组合物、胶囊制剂及其制备方法 |
CN116672309A (zh) * | 2023-07-26 | 2023-09-01 | 北京普诺旺康医药科技有限公司 | 干混悬药物组合物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4992419A (en) * | 1987-05-09 | 1991-02-12 | Boehringer Mannheim Gmbh | Stabilized erythropoietin preparations |
US5451410A (en) * | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
CN1190897A (zh) * | 1995-07-14 | 1998-08-19 | 诺沃挪第克公司 | 含有用锌及选择性的赖氨酸或者钙离子预处理过的生长激素的稳定药物组合物 |
US20050020811A1 (en) * | 2003-01-28 | 2005-01-27 | Currie Mark G. | Methods and compositions for the treatment of gastrointestinal disorders |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH658973A5 (fr) | 1983-12-29 | 1986-12-31 | Nestle Sa | Produit aromatisant. |
JPS6197229A (ja) * | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
JPS649938A (en) | 1987-06-30 | 1989-01-13 | Agency Ind Science Techn | Oral ingestive composition |
EP0420964A4 (en) | 1989-04-11 | 1991-09-25 | Immunobiology Research Institute, Inc. | Lyophilized peptide formulations |
IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
US5221495A (en) | 1990-04-13 | 1993-06-22 | Colgate-Palmolive Company | Enzyme stabilizing composition and stabilized enzyme containing built detergent compositions |
US6284727B1 (en) | 1993-04-07 | 2001-09-04 | Scios, Inc. | Prolonged delivery of peptides |
US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
US5654278A (en) * | 1994-10-13 | 1997-08-05 | Novo Nordisk A/S | Composition and method comprising growth hormone and leucine |
IL115592A (en) * | 1994-10-13 | 2000-07-26 | Novo Nordisk As | Stabilized pharmaceutical formulation comprising a growth hormone and leucine |
US5593696A (en) * | 1994-11-21 | 1997-01-14 | Mcneil-Ppc, Inc. | Stabilized composition of famotidine and sucralfate for treatment of gastrointestinal disorders |
US5904935A (en) | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US5932547A (en) | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
US5916582A (en) | 1996-07-03 | 1999-06-29 | Alza Corporation | Aqueous formulations of peptides |
IL127769A (en) | 1996-07-03 | 2006-10-31 | Alza Corp | Non-aqueous protic preparations of peptides |
US20020151502A1 (en) * | 1997-10-09 | 2002-10-17 | Albert Sattin | Tri-peptides for neurological and neurobehavior applications |
US6541606B2 (en) | 1997-12-31 | 2003-04-01 | Altus Biologics Inc. | Stabilized protein crystals formulations containing them and methods of making them |
US6087478A (en) | 1998-01-23 | 2000-07-11 | The Rockefeller University | Crystal of the N-terminal domain of a STAT protein and methods of use thereof |
JP2002521322A (ja) | 1998-07-23 | 2002-07-16 | ノボ ノルディスク アクティーゼルスカブ | 安定な医薬製剤の製造のための湿式顆粒化方法 |
AU6462099A (en) * | 1998-09-04 | 2000-03-27 | Gaplast Gmbh | Container |
AU766293B2 (en) | 1998-11-27 | 2003-10-16 | Kanji Takada | An oral formulation for gastrointestinal drug delivery |
WO2001052937A1 (en) | 2000-01-24 | 2001-07-26 | Medtronic Minimed, Inc. | Mixed buffer system for stabilizing polypeptide formulations |
JP4711520B2 (ja) * | 2000-03-21 | 2011-06-29 | 日本ケミカルリサーチ株式会社 | 生理活性ペプチド含有粉末 |
HUP0301802A3 (en) | 2000-06-28 | 2009-04-28 | Teva Pharma | Process for producing carvedilol, crystalline carvedilol, process for producing it and pharmaceutical composition containing it |
FR2811884B1 (fr) | 2000-07-21 | 2003-01-31 | Oreal | Utilisation en cosmetique de betainates d'amidon et composition les comprenant associes a au moins un agent benefique pour les matieres keratiniques |
US6613308B2 (en) | 2000-09-19 | 2003-09-02 | Advanced Inhalation Research, Inc. | Pulmonary delivery in treating disorders of the central nervous system |
WO2002026248A1 (en) | 2000-09-29 | 2002-04-04 | Cognetix, Inc. | Stable peptide formulations |
ES2281458T3 (es) | 2000-12-21 | 2007-10-01 | Nektar Therapeutics | Composiciones de polvo estables en almacenamiento del receptor de interleucina 4. |
JP2004521123A (ja) | 2001-02-02 | 2004-07-15 | ファルマシア・コーポレーション | 腸癌阻害のためのウログアニリンおよびシクロオキシゲナーゼ−2阻害薬の組合わせ |
GB0104371D0 (en) | 2001-02-22 | 2001-04-11 | Clariant Int Ltd | Color improving stabilizing compositions comprising leucine |
US6573237B2 (en) | 2001-03-16 | 2003-06-03 | Eli Lilly And Company | Protein formulations |
CN103638514A (zh) | 2001-03-29 | 2014-03-19 | 药物协和公司 | 用于治疗组织炎症和癌变的鸟苷酸环化酶受体激动剂 |
WO2003014304A2 (en) | 2001-08-09 | 2003-02-20 | Doctor's Signature Sales And Marketing International Corp. [(Dba)] Life Force International | Protonic formulation |
US20030104996A1 (en) | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
IL162618A0 (en) * | 2001-12-21 | 2005-11-20 | Novo Nordisk As | Liquid composition of modified factor vii polypeptides |
JP2003201256A (ja) | 2001-12-28 | 2003-07-18 | Hisamitsu Pharmaceut Co Inc | 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤 |
DE10261126A1 (de) * | 2002-08-13 | 2004-03-04 | Aventis Behring Gmbh | Lagerungsstabile, flüssige Fibrinogen-Formulierung |
KR20050088311A (ko) | 2002-12-11 | 2005-09-05 | 화이자 프로덕츠 인크. | 고지방 환경 내로의 활성 물질의 조절-방출 |
US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DK2246360T3 (da) | 2003-01-28 | 2012-08-13 | Ironwood Pharmaceuticals Inc | Sammensætninger til behandlingen af gastrointestinale lidelser |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
DK1638586T3 (da) | 2003-05-14 | 2008-06-23 | Indus Biotech Pvt Ltd | Synergistisk sammensætning til behandling af diabetes mellitus |
KR100610003B1 (ko) * | 2003-06-10 | 2006-08-08 | 주식회사 엘지생명과학 | 혈청 알부민을 함유하지 않는 안정한 인 에리쓰로포이에틴용액 제형 |
US7494979B2 (en) | 2003-06-13 | 2009-02-24 | Ironwood Pharmaceuticals, Inc. | Method for treating congestive heart failure and other disorders |
PL1644021T3 (pl) | 2003-06-13 | 2013-01-31 | Ironwood Pharmaceuticals Inc | Sposoby i kompozycje do leczenia zaburzeń żołądkowo-jelitowych |
KR100560697B1 (ko) | 2003-08-06 | 2006-03-16 | 씨제이 주식회사 | 알부민을 함유하지 않는 에리스로포이에틴 제제 |
DE202004020676U1 (de) | 2004-03-10 | 2005-11-10 | Bioceuticals Arzneimittel Ag | Erythropoietin-Flüssigformulierung |
JP4744533B2 (ja) | 2004-12-30 | 2011-08-10 | ドゥビエル カンパニー リミテッド | 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法 |
US20090253634A1 (en) | 2005-08-19 | 2009-10-08 | Microbia, Inc. | Methods and Compositions for the Treatment of Gastrointestinal Disorders |
WO2007044375A2 (en) | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
CA2642761A1 (en) * | 2006-02-23 | 2007-08-30 | Iomedix Sleep International Srl | Compositions and methods for the induction and maintenance of quality sleep |
US20090305993A1 (en) | 2006-02-24 | 2009-12-10 | Ironwood Pharmaceuticals, Inc. | Methods and composition for the treatment of gastrointestinal disorders |
ITMI20060629A1 (it) | 2006-03-31 | 2007-10-01 | Daniele Giovannone | Composizioni solide orali a base di s-adenosilmetionina e processo per il loro ottenimento |
ES2532392T3 (es) | 2006-07-10 | 2015-03-26 | Pba3 Biomed Gmbh | Péptidos antimicrobianos |
EP3421031A1 (en) | 2006-08-09 | 2019-01-02 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
JP5042312B2 (ja) | 2006-08-31 | 2012-10-03 | ノバルティス アーゲー | Hghを含む経口送達用医薬組成物 |
CA2673260A1 (en) * | 2006-12-20 | 2008-07-03 | Bayer Healthcare Llc | Factor vii and viia compositions |
EP2129683A4 (en) | 2007-02-26 | 2011-01-05 | Ironwood Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATMENT OF HEART FAILURE AND OTHER DISORDERS |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
SI2328601T1 (sl) | 2008-08-15 | 2020-08-31 | Ironwood Pharmaceuticals, Inc. | Linaklotid vsebujoče formulacije za oralno dajanje |
EP2331077A2 (en) | 2008-09-04 | 2011-06-15 | Ironwood Pharmaceuticals, Inc. | Stable forlulation comprising therapeutic polypeptides for oral administration |
EP2341898A2 (en) * | 2008-09-04 | 2011-07-13 | Ironwood Pharmaceuticals, Inc. | Stable solid formulations of gc-c receptor agonist polypeptides suitable for oral administration |
JP5964589B2 (ja) * | 2008-12-03 | 2016-08-03 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcアゴニストの製剤およびその使用方法 |
US20130012454A1 (en) * | 2009-07-06 | 2013-01-10 | Ironwood Pharmaceuticals, Inc. | Orally Disintegrating Compositions of Linaclotide |
JP2013501071A (ja) | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ, インコーポレイテッド | リナクロチドを含む処方物 |
MX2012001691A (es) * | 2009-08-12 | 2012-02-29 | Forest Lab Holdings Ltd | Composiciones de linaclotida que se desintegran oralmente. |
-
2009
- 2009-08-14 SI SI200932048T patent/SI2328601T1/sl unknown
- 2009-08-14 CN CN202210243774.1A patent/CN114668711A/zh active Pending
- 2009-08-14 PT PT97891428T patent/PT2328601T/pt unknown
- 2009-08-14 EP EP09789142.8A patent/EP2328601B1/en active Active
- 2009-08-14 RS RS20200341A patent/RS60101B1/sr unknown
- 2009-08-14 KR KR1020117005886A patent/KR101704832B1/ko active IP Right Grant
- 2009-08-14 LT LTEP09789142.8T patent/LT2328601T/lt unknown
- 2009-08-14 KR KR1020227022715A patent/KR20220100101A/ko not_active Application Discontinuation
- 2009-08-14 HU HUE09789142A patent/HUE049023T2/hu unknown
- 2009-08-14 KR KR1020197037905A patent/KR20200000462A/ko not_active Application Discontinuation
- 2009-08-14 ES ES09789142T patent/ES2785980T3/es active Active
- 2009-08-14 KR KR1020177034889A patent/KR20170138580A/ko active Application Filing
- 2009-08-14 KR KR1020237004083A patent/KR20230025926A/ko not_active Application Discontinuation
- 2009-08-14 KR KR1020187036664A patent/KR20180137043A/ko not_active Application Discontinuation
- 2009-08-14 NZ NZ591713A patent/NZ591713A/xx unknown
- 2009-08-14 KR KR1020217037760A patent/KR20210145307A/ko not_active Application Discontinuation
- 2009-08-14 US US12/541,410 patent/US8802628B2/en active Active
- 2009-08-14 PE PE2015000686A patent/PE20151205A1/es unknown
- 2009-08-14 US US13/059,154 patent/US20120213846A1/en not_active Abandoned
- 2009-08-14 WO PCT/US2009/004675 patent/WO2010019266A2/en active Application Filing
- 2009-08-14 CA CA2732892A patent/CA2732892C/en active Active
- 2009-08-14 EP EP20152529.2A patent/EP3701962A1/en active Pending
- 2009-08-14 MX MX2011001620A patent/MX2011001620A/es active IP Right Grant
- 2009-08-14 CN CN201810378167.XA patent/CN109010254A/zh active Pending
- 2009-08-14 SG SG2013062054A patent/SG193801A1/en unknown
- 2009-08-14 JP JP2011523004A patent/JP5770629B2/ja active Active
- 2009-08-14 PE PE2011000151A patent/PE20110543A1/es active IP Right Grant
- 2009-08-14 GE GEAP200912142A patent/GEP20156209B/en unknown
- 2009-08-14 BR BRPI0917807-4A patent/BRPI0917807A2/pt not_active Application Discontinuation
- 2009-08-14 DK DK09789142.8T patent/DK2328601T3/da active
- 2009-08-14 KR KR1020217010732A patent/KR20210043728A/ko not_active Application Discontinuation
- 2009-08-14 KR KR1020207025119A patent/KR20200105730A/ko not_active Application Discontinuation
- 2009-08-14 CN CN201510363805.7A patent/CN105168114A/zh active Pending
- 2009-08-14 MX MX2020005326A patent/MX2020005326A/es unknown
- 2009-08-14 KR KR1020247004930A patent/KR20240025699A/ko active Application Filing
- 2009-08-14 CN CN200980140931.9A patent/CN102186490B/zh active Active
- 2009-08-14 CN CN202311333813.8A patent/CN117530912A/zh active Pending
- 2009-08-14 EA EA201170337A patent/EA201170337A1/ru unknown
- 2009-08-14 KR KR1020177002833A patent/KR20170016522A/ko not_active Application Discontinuation
- 2009-08-14 PL PL09789142T patent/PL2328601T3/pl unknown
- 2009-08-14 AU AU2009282446A patent/AU2009282446B2/en active Active
-
2011
- 2011-02-03 IL IL211028A patent/IL211028A/en active IP Right Grant
- 2011-02-11 MX MX2019013628A patent/MX2019013628A/es unknown
- 2011-02-14 CL CL2011000314A patent/CL2011000314A1/es unknown
- 2011-02-18 CO CO11019927A patent/CO6351746A2/es active IP Right Grant
- 2011-02-25 ZA ZA2011/01523A patent/ZA201101523B/en unknown
-
2012
- 2012-03-12 HK HK12102460.3A patent/HK1161978A1/zh unknown
-
2013
- 2013-03-15 US US13/837,631 patent/US20130273169A1/en not_active Abandoned
-
2014
- 2014-04-28 JP JP2014092883A patent/JP6034327B2/ja active Active
-
2015
- 2015-07-16 PH PH12015501579A patent/PH12015501579B1/en unknown
-
2016
- 2016-06-22 HK HK16107217.4A patent/HK1219062A1/zh unknown
- 2016-08-03 JP JP2016152831A patent/JP2016190870A/ja not_active Withdrawn
-
2018
- 2018-04-02 JP JP2018070899A patent/JP2018104469A/ja not_active Withdrawn
- 2018-04-02 JP JP2018070898A patent/JP6473532B2/ja active Active
- 2018-09-13 US US16/129,951 patent/US20190029967A1/en not_active Abandoned
-
2019
- 2019-07-08 JP JP2019126707A patent/JP2019163340A/ja not_active Withdrawn
-
2020
- 2020-03-28 HR HRP20200512TT patent/HRP20200512T1/hr unknown
- 2020-04-13 CY CY20201100342T patent/CY1122801T1/el unknown
-
2021
- 2021-02-08 JP JP2021018125A patent/JP2021073297A/ja not_active Withdrawn
- 2021-06-02 US US17/336,462 patent/US20210290554A1/en not_active Abandoned
-
2022
- 2022-01-07 US US17/570,713 patent/US20220125734A1/en not_active Abandoned
- 2022-07-12 JP JP2022111842A patent/JP2022132383A/ja not_active Withdrawn
-
2023
- 2023-04-14 US US18/134,977 patent/US20230310329A1/en not_active Abandoned
- 2023-12-12 JP JP2023209257A patent/JP2024015361A/ja active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4992419A (en) * | 1987-05-09 | 1991-02-12 | Boehringer Mannheim Gmbh | Stabilized erythropoietin preparations |
US5451410A (en) * | 1993-04-22 | 1995-09-19 | Emisphere Technologies, Inc. | Modified amino acids for encapsulating active agents |
CN1190897A (zh) * | 1995-07-14 | 1998-08-19 | 诺沃挪第克公司 | 含有用锌及选择性的赖氨酸或者钙离子预处理过的生长激素的稳定药物组合物 |
US20050020811A1 (en) * | 2003-01-28 | 2005-01-27 | Currie Mark G. | Methods and compositions for the treatment of gastrointestinal disorders |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109010254A (zh) | 适合口服给药的鸟苷酸环化酶-c受体激动剂多肽的稳定的固体制剂 | |
US20150132375A1 (en) | Stable Solid Formulation of a GC-C Receptor Agonist Polypeptide Suitable for Oral Administration | |
TWI531374B (zh) | 適於口服之gc-c受體激動劑多肽之穩定固態調配物 | |
EA040381B1 (ru) | Стабильная твердая композиция полипептидного агониста gc-c рецептора, приемлемая для перорального введения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181218 |